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EFFICIENT AND SELECTIVE GENE TRANSFER DIRECTED TO MUSCLE BY 
TROPISM-MODIFIED ADENO-ASSOCIATED VIRUS VECTOR 
 
 Chi-Yi Yu, PhD 
University of Pittsburgh, 2007 
 
         Gene therapy offers a promise for treating inherited muscle disorders. The advantages of 
recombinant adeno-associated virus (rAAV) gene delivery vector include nonpathogenicity and 
long-term gene expression after a single administered dose. However, rAAV predominantly 
transduces the liver after systemic administration, reducing its efficiency for gene transfer to 
the heart and skeletal muscle. The question of how to deliver the therapeutic genes into most of 
the diseased myofibers becomes a challenge. The goal of this project is to develop an efficient 
and muscle-specific AAV vector for systemic delivery. Here, the muscle-targeting peptide 
ASSLNIA was incorporated into AAV2 capsid after residue 587 without heparin-binding motif 
(587 TG MTP vector) or with heparin-binding motif (588 HB MTP vector) since heparan 
sulfate is the primary cellular receptor of AAV2. The efficiencies and selectivities of muscle 
targeting of modified rAAVs were evaluated in vitro and in vivo. 
         This study demonstrated that the peptide-modified vectors maintained their myotube 
transduction ability. Peptide-engineered AAVs decreased their transductions in non-muscle 
cell lines. In addition, the 587 TG MTP vector did not require the heparin-dependent 
mechanism for muscular targeting. The C2C12 myotube transductions of 587 TG MTP and 
588 HB MTP vectors were inhibited 47%~58% in the presence of free ASSLNIA peptide 
while unmodified rAAV2 transduction was only suppressed by 25%. To explore the muscle-
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targeting abilities of modified rAAVs in vivo, mice were injected intravenously via a tail vein 
with a viral dose containing 9x1011 genomic particles. After four weeks, mouse organs were 
harvested for the luciferase assay. The 587 TG MTP vector demonstrated enhanced muscle and 
heart transduction compared to unmodified rAAV2. Importantly, the 587 TG MTP virus 
significantly reduced its transduction of liver, lungs, and spleen. The vector biodistribution in 
organs was also determined by real-time PCR and peptide-modified vectors showed similar 
targeting effects. Moreover, this study found that both 587 TG MTP and 588 HB MTP vectors 
were resistant to antibody neutralization.  
         These results indicate that this muscle-targeting peptide facilitates the generation of an 
efficient and muscle-specific AAV vector for systemic gene delivery in the treatment of muscle 
diseases to provide clinical and public health benefits.  
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1. INTRODUCTION 
1.1 Muscular dystrophy 
1.1.1 Clinical definition and classification 
Muscular dystrophies (MDs) are a heterogeneous group of hereditary disorders characterized by 
progressive muscle wasting and weakness. Typical features of dystrophic muscle include 
variation in myofiber size, infiltration of fat and connective tissue, areas of muscle necrosis, and 
centrally located nuclei. Dystrophic myofiber membranes are fragile, so extensive damage 
occurs and causes muscle necrosis and wasting. MD often affects multiple systems. Death is 
usually due to respiratory insufficiency or cardiac failure in patients with MD. Although MD 
presents a vast clinical variability regarding age of onset, pattern of skeletal muscle involvement, 
degree of severity, and rate of disease progression, the original classification of MD depends on 
the distribution of predominant muscle weakness and the mode of inheritance (1). According to 
the basis of classification, several major groups have been defined. Three identified principal 
types of MD are a) Duchenne and Becker muscular dystrophies (DMD and BMD), b) limb girdle 
muscular dystrophy (LGMD), and c) facioscapulohumeral muscular dystrophy (FSHD). 
Myotonic dystrophy (DM) is the most common adult MD. Emery-Dreifuss muscular dystrophy 
(EDMD) is delineated as a rare form of MD. Congenital muscular dystrophy (CMD), distal 
muscular dystrophy, and oculopharyngeal muscular dystrophy (OPMD) are relatively uncommon 
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groups. Clinical signs and symptoms are important for the physical examination, but 
immunohistochemistry and DNA based mutation analysis have made it feasible to establish 
precise diagnosis of the dystrophies. 
1.1.2 Epidemiology 
Since DMD has been clearly characterized for many years, its distribution and incidence are well 
established. DMD patients are present all over the world. The prevalence of DMD has been 
repeatedly evaluated in many countries. The study shows that DMD affects 1 in every 3,500 live 
male births, regardless of race or nationality (2). Most DMD patients have a family history of 
MD, but de novo mutations of the dystrophin gene occur in one-third of cases (3). 
         In contrast to DMD, some types of dystrophy are especially frequent in certain populations. 
For example, the incidences of several autosomal recessive LGMDs in Brazil, North America, 
and the Middle East are frequent, but they are rare elsewhere. Fukuyama CMD is often found in 
Japan, while the autosomal dominant distal muscular dystrophy is most common in Scandinavia. 
OPMD usually exists in French Canadian families (4). 
1.1.3 Pathogenesis 
The genetic basis of more than 30 different dystrophies has been explored. The defective gene in 
MD results in the dysfunction of muscle proteins, including cytoskeletal proteins, basement 
membrane proteins, transmembrane proteins, proteases, and nuclear envelop proteins. The 
molecular studies of these mutations lead to insights into the pathogenesis of MD. MDs often 
impair multiple system functions. In addition to the skeletal muscle weakness, cardiac 
complications are symptomatic of many MD disorders. The understanding of the pathogenesis 
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for cardiac involvement in different MDs allows us to develop more effective management and 
treatment for MD patients. Certain dystrophies possess successive cycles of degeneration and 
regeneration of muscle fibers. Muscle necrosis triggers local inflammation with subsequent 
infiltration of mononuclear cells into necrotic lesions. Inflammatory changes in the muscle may 
enhance muscle damage and accelerate the pathogenic progression. 
         DMD is the most severe and common form of dystrophy. It is a lethal X-linked recessive 
disorder and predominantly affects boys. DMD patients typically lack clinical symptoms at birth. 
Initial signs of muscle weakness in the DMD patient generally present at the age of 2~5 years. 
Twenty percent of affected boys have intellectual impairment. Progressive muscle wasting is 
persistent and mainly affects proximal muscle function with a decrease in lower limb strength 
(5). Because of continuous muscle wasting, most DMD boys lose their ambulation and become 
wheelchair-bound by age 12. Death usually occurs in the teens or early twenties from respiratory 
or cardiac failure (6).  
         In 1987, the gene responsible for DMD was cloned and the gene product was subsequently 
named dystrophin (7-9). The human dystrophin gene is identified on chromosome Xp21 (10, 11). 
The dystrophin gene is the largest gene in association with a disease and encodes a 427 kDa 
cytoskeletal protein. Dystrophin protein is predominantly expressed in smooth, cardiac, and 
skeletal muscle (12). It also can be detected in brain at a lower level (13). Dystrophin comprises 
four structural domains: a) the amino-terminal actin-binding domain, b) a central rod domain, c) 
a cysteine-rich domain, and d) a carboxy-terminal domain (14, 15). The dystrophin-glycoprotein 
complex (DGC) is a transmembrane protein complex and its primary function is to maintain 
muscle membrane integrity. In addition to dystrophin, the DGC contains the dystroglycan (DG) 
complex of α and β-DG, the sarcoglycans (α, β, γ, and δ-SG), sarcospan, a pair of syntrophins, 
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and dystrobrevin. The amino acid terminus of dystrophin binds to actin filaments (F-actin) of the 
intracellular cytoskeleton (16, 17). The carboxy-terminal of dystrophin inside the muscle cell 
interacts with β-DG, a transmembrane protein that associates with α-DG in the extracellular 
matrix (ECM). Extracellular α-DG binds to laminin-2 of the basal lamina and thus links the 
internal cytoskeleton to the ECM (18). Mutations in genes encoding the DGC components lead 
to 12 distinct dystrophies; therefore, the DGC complex has its fundamental importance in the 
pathogenesis of MD.  
         55-65% of DMD cases are caused by delections of one or more exons of dystrophin gene.  
No functional dystrophin protein is produced in DMD patient although a few “revertant” fibers 
expressing dystrophin are occasionally seen due to the possible frame-restoring exon-skipping 
(19). Absence of dystrophin expression hampers the DGC formation and further causes 
membrane destabilization during muscle contraction. The loss of membrane integrity induces the 
presence of necrotic myofibers, so necrosis elicits repeated cycles of degeneration and 
regeneration on muscle. Eventually the regenerative capacity of muscle satellite cells is no longer 
effective, and muscle mass is gradually replaced by fat and connective tissue. This myopathic 
process gives rise to the progressive muscle wasting and severe systemic muscle dysfunction in 
DMD.  
         BMD and DMD are termed dystrophinopathy because both diseases are caused by a variety 
of defects in the dystrophin gene (20). In BMD, the aberrant changes of dystrophin gene are 
“missense” mutations or deletions that preserve the reading frame and allow the synthesis of a 
truncated or semifunctional dystrophin molecule (21). The distributions of muscle weakness and 
wasting among BMD and DMD patients are similar; however, BMD patients have a milder 
disease course because they have partly functional dystrophin. The age of onset in BMD patients 
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is usually in the teenage years and some of them do not present the clinical symptoms until a 
much later age. Most of BMD patient are alive at the age of twenty and usually die in their 
forties or fifties. Some BMD patients still remain mobile until old age. DMD and BMD carriers 
are at risk of developing dilated cardiomyopathy (DCM). In BMD, the severity of cardiac 
diseases does not depend on the progression of skeletal muscle weakness. BMD patients can 
suffer from severe DCM with relatively well-preserved skeletal muscle function.    
         LGMDs are characterized by the predominant muscle weakness and wasting of the pelvic 
or shoulder girdle musculature with normal intelligence. These diseases have a great variability 
of age of onset. Milder forms have adult onset with slower progression. Conversely, severe 
forms exhibit childhood onset and an aggressive course. So far, at least 17 LGMDs have been 
defined and 13 genetic loci are identified for these disorders (22, 23). LGMDs can be divided 
into two groups. Less than 10% of patients have an inherited autosomal dominant trait (type 1) 
and are comparatively mild. The rest of LGMD cases display an inherited autosomal recessive 
trait (type 2) which affects both males and females. The type 2 LGMD diseases are often more 
severe.    
         Five different genes have been associated with autosomal dominant LGMDs. LGMD1A 
has the mutation in myotilin gene, a protein component of sarcomere (24). The sarcomere is the 
smallest functional unit of the striated muscle contraction apparatus and the actin/myosin 
movement takes place in the sarcomere. Mutations in sarcomeric protein components disrupt 
muscle contractile function, causing MD. Thus, they give rise to MD. LGMD1B is a rare 
autosomal dominant form of MD with cardiac involvement (25). The gene responsible for 
LGMD1B, an allelic disorder of EDMD, is lamin A/C. Lamin A/C is a nuclear envelope protein 
and the mutation of lamin A/C leads to an increase of nuclear fragility during mechanical stress. 
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The locus for LGMD1C is caveolin-3. Caveolin-3 is a muscle specific membrane protein (26). 
Caveolin-3 is expressed upon muscle differentiation and may be involved in the regulation of 
glycolysis in muscles through the binding to the muscle-specific isoform of phosphofructokinase 
(PFK-M) (27). The mechanism of caveolin-3 disruption resulting in MD remains speculative; 
however, it may be the failure of proper signal transduction events. 
         In autosomal recessive LGMDs, LGMD2A is the most prevalent form of LGMD and is the 
first case of progressive MD resulting from an enzymatic defect. LGMD2A patients have a 
mutation in the calpain-3 gene (28). Calpain-3 is an intracellular calcium-activated cysteine 
protease and it has the ability to regulate NF-κB activity via proteolysis. Patients exhibit a failure 
of nuclear localization of the cell survival mediator, NF-κB, and they have more apoptotic nuclei 
in their muscles. This suggests that the calpain-3 deficiency may block expression of cell 
survival genes in MD. LGMD2B arises from mutations in the dysferlin gene (29). Dysferlin is a 
plasma membrane protein involved in the membrane repair machinery of skeletal muscle. The 
role of dysferlin is to accumulate and to fuse vesicles near the site of membrane disruption to 
effect membrane repair. Loss of the membrane repair component further impairs the survival of 
muscle cells after extrinsic or intrinsic damages. LGMD 2C, 2D, 2E, and 2F associate with the 
mutations in genes encoding γ-, α-, β-, and δ-SG, respectively (30-33). The SGs are integral 
components of the DGC and seem to have a critical role in the stabilization of the DGC. A 
primary mutation in any one of the SGs may cause the destabilization of entire DGC complex 
and have substantial disruption of the plasma membrane. In striated muscle, β- and δ-SG form a 
core and then α- and γ-SG bind to this core before sarcoglycan complex maturation and targeting 
to the sarcolemma (34). LGMD2E and LGMD2F are severe clinical phenotypes of LGMD and 
they are associated with cardiomyopathy. Analysis of muscle from LGMD2G patients indicates 
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mutation of the telethonin gene (35). Telethonin is the sarcomertic protein that interacts with 
titin. Mutations of telethonin do not disrupt the sarcomeric architecture. This finding suggests 
that muscle degeneration in LGMD2G patients is more likely due to a functional defect than to 
disruption of sarcomeric structure. LGMD2H is caused by a ‘‘missense’’ mutation in the 
TRIM32 gene. TRIM32 may be an E3-ubiquitin ligase that contributes to the ubiquitin-
proteosome pathway (36). The TRIM32 deficiency could dysregulate protein degradation in the 
muscle. The fukutin-related protein (FKRP) mutation is identified in LGMD2I patients (37). 
FKRP localizes to the Golgi apparatus and it plays a role in modification of cell surface 
glycoproteins and glycolipids. LMD2I patients show a variable reduction of α-DG on 
sarcolemma. The unusual expression of α-DG is a consequence of its abnormal glycosylation, 
which is the pathogenetic mechanism of LGMD2I. LGMD2I patients frequently develop DCM. 
Titin gene mutations cause LGMD2J, a severe form of LGMD. Titin is a central sarcomeric 
myofilament that is expressed in heart and skeletal muscle (38). Titin has an important role for 
the assembly of actin and myosin in the sacromere. One of the principal effects of titin is to keep 
myosin centrally located in the sarcomere during cycles of contraction. Mutations in titin affect 
the development of balanced force in the sarcomere and may cause continuous mechanical 
muscle damage resulting in MD.  
         FSHD is inherited as an autosomal dominant trait. The deletion of a tandemly repeated 3.3 
kb sequence on chromosome 4q35 is highly associated with FSHD dystrophy (39). However, a 
single gene defect causing FSHD has not been identified. FSHD patients initially have facial 
muscle weakness and develop lower limb weakness in the later disease course. The uncommon 
symptoms, such as retinal vascular diseases, hearing loss, and abnormalities in the central 
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nervous system (CNS), may occur. Many patients are mildly affected by FSHD, but some 
patients are more severe and may become wheelchair-confined. 
         DM most commonly occurs in adolescence or adult life and is usually caused by an 
unstable CTG trinucleotide repeat at chromosome 19q13.3. Two types of DM have been 
characterized. DM type 1 is caused by an expansion of this CTG repeat at the three prime 
untranslated region (3' UTR) of the myotonic dystrophy protein kinase (DMPK) gene. DM type 
2 is involved in a CCTG expansion located in an intron of the zinc finger protein 9 (ZNF9) gene 
(23). Myotonia with muscle weakness and wasting occurs in DM patients. 
         At least three EDMD diseases have been reported and all of them are caused by mutations 
in genes coding for nuclear envelope proteins. A mutation in the emerin gene causes X-linked 
EDMD (40). The less common autosomal dominant and recessive forms of EDMD have 
mutations in the lamin A/C gene (41). Emerin interacts with lamin A and lamin C in the nucleus 
(42). It is predicted that mutations in emerin or lamin A/C locus perturb the integrity of the 
nuclear membrane and increase the cell susceptibility to apoptosis. Some reports also indicate 
that these mutations disturb the regulation of gene expression by abnormal control of nuclear 
mRNA release (43). EDMD predominantly presents with contractures of the spine, elbows, and 
Achilles tendons with mild muscle weakness in a humeroperonal distribution. All individuals 
with EDMD, irrespective of the mode of inheritance, have the serious risk of cardiac conduction 
defects.     
         CMD is a relatively uncommon autosomal recessive group of myogenic disorders. The 
clinical features present at birth or in the first few months of life. CMD patients have hypotonia, 
generalized muscle weakness, contractures, and motor development delay. Some types of CMD 
may lead to mental retardation due to structural defects within brain. Based on the expression of 
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laminin α2 (also known as merosin), CMD is divided into merosin-negative and merosin-
positive groups. Compared to the merosin-positive group, the merosin-negative cases of CMD 
are more severe and they often develop serious respiratory problems. MDC1A (muscular 
dystrophy, congenital, type 1A) is associated with mutations in the LAMA2 gene located on 
chromosome 6q2 and contributes to 40% of CMD cases (44). MDC1A individuals present a 
primary total or partial deficiency of laminin α2 (45, 46). Laminin α2 is the extracellular muscle 
protein that bridges the interaction between α-DG and the basal lamina. In MDC1A patients, 
laminin α2-deficiency disrupts the basal lamina resulting in a loss of the stability of muscle 
cytoskeletal network. MDC1C and LGMD2I are allelic disorders, due to mutations in the FKRP 
gene (47). Both types have a variable reduction of α-DG, but not β-DG. The amount of α-DG 
expression is associated with the clinical severity. Individuals with the severe disease course of 
MDC1C present a profound depletion of α-DG resulting from abnormal glycosylation. As in 
LGMD2I, DCM is also common in MDC1C individuals. Muscle biopsies from MDC1C patients 
typically show a secondary deficiency of laminin α2, while a secondary reduction of calpain-3 
and laminin β1 is observed in the muscle biopsy of LGMD2I. Defects in a number of 
glycosyltransferases are responsible for several CMDs, such as MDC1D, muscle-eye-brain 
disease (MEB), Walker Warburg syndrome (WWS), and Fukuyama congenital muscular 
dystrophy (FMDC). These types of CMD are characterized by severe muscle weakness and 
mental retardation. They cause aberrant hypoglycosylation of α-DG leading to the dystrophic 
phenotype (48). The LARGE gene encoding a putative glycosyltranferase is associated with 
MDC1D (49). POMGnT1 is an O-linked mannose β1, 2 N-acetylglucosaminytransferase and 
MEB patients have mutations in the POMGnT1 gene (50). Mutations in POMT1, a 
mannosyltransferase, only account for 20% of WWS cases. The severe “nonsense” mutations in 
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the fukutin gene also display WWS (51, 52). In Japan, FMDC is the second most common form 
of MD and is caused by mutations in the fukutin gene. The enzymatic activity of fukutin protein 
probably controls the modification of cell surface glycoproteins. Fukutin protein is located in the 
Golgi body and secretory granules. Moreover, it is involved in neuronal migration (53, 54). The 
loss of fukutin protein in FMDC also elicits the secondary protein deficit of merosin and the 
DGC complex. Collagen VI is an extracellular matrix protein and its expression has been found 
in a wide variety of tissues (55). It consists of three polypeptide chains. These chains are α1, α2, 
and α3 encoded, respectively, by the COL6A1 and COL6A2 genes on chromosome 21q22.3 and 
the COL6A3 gene on chromosome 2q37. Collagen VI plays a role in anchoring the muscle fiber 
basement membrane to the extracellular matrix (56-59). Additionally, collagen VI seems to 
transmit signals from the etxracellular to the intracellular space through the binding to cellular 
transmembrane receptors, such as integrins (60). In this way, collagen VI induces cell 
proliferation and inhibits apoptosis (61, 62). Mutations in all three collagen VI genes lead to two 
types of CMD, the more severe Ullrich muscular dystrophy (UMDC) and the milder Bethlem 
myopathy (63, 64). The deficiency of collagen VI results in the unexpected apoptosis due to the 
presence of aberrant structure alterations in mitochondria and sarcoplasmic reticulum (SR) (65). 
RSMD1 (or rigid spine syndrome) is a selenoprotein N (SEPN1) deficient CMD due to 
mutations in the SEPN1 gene (66). SEPN1 protein is a membrane-bound glycoprotein in the 
rough endoplasmic reticulum and the function of SEPN1 protein may regulate protein trafficking 
and processing (67). The expression level of SEPN1 protein is high in the diaphragm, which 
explains the severe restrictive respiratory syndrome in RSMD1 patients. Integrins are 
transmembrane glycoproteins expressed in skeletal muscle, especially at the sarcolemma, 
neuromuscular junction and myotendinous junction. They act as the cell surface receptors and 
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provide a link between the actin cytoskeleton and the extracellular matrix. In addition, integrins 
play an essential role in muscle differentiation during embryonic development. The major 
laminin receptor in skeletal, cardiac, and smooth muscle is integrin α7β1 (68-70). Mutations in 
the integrin α7 gene cause the destruction of the myotendinous junction and lead to a mild form 
of CMD in humans (71-73). 
         Distal muscular dystrophy is divided into autosomal recessive inheritance leading to early 
onset (less than 30 years of age) and autosomal dominant inheritance with late onset (over 40 
years of age). The autosomal recessive form, Miyoshi myopathy (MM), and LGMD2B are allelic 
disorders. Both diseases have mutations in the gene encoding dysferlin, but they differ in the 
distribution of muscle weakness at onset (74-76). Tibial muscular dystrophy (TMD) is an 
autosomal dominant distal myopathy. TMD and LGMD2J have the same mutation in the titin 
gene. If the mutation in the titin gene appears in homozygous form, it can cause LGMD2J. 
Otherwise, a heterozygous mutation in the titin gene presents as TMD (77-79). The difference 
between LGMDs and distal muscular dystrophies is that distal myopathies primarily attack the 
distal musculature without conspicuous involvement of other muscle group while LGMDs 
display predominant muscle weakness and wasting of the pelvic or shoulder girdle musculature. 
         OPMD is characterized by extraocular muscle weakness, ptosis, dysphagia, and weakness 
in neck and proximal upper limb muscles (80). The first exon of the PABP2 gene encoding the 
poly-(A)-binding protein normally contains a (GCG)6 triplet repeat. However, there is an 
addition of two to seven (GCG) repeats in OPMD individuals. The triplet repeat expansion 
impedes normal transport of mRNA from the nucleus (81). 
         The discovery of the dystrophin gene and its role in causing DMD has facilitated the 
development of research on the elucidation of MD pathogenesis. Many types of MD are caused 
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by muscle membrane instability due to the loss of a network between the intracellular 
cytoskeleton and the extracellular matrix. Nevertheless, the pathogenesis of MD appears to be 
more complicated. Future studies should also focus on the signaling pathways controlling MD.                            
1.1.4 Therapeutic approaches  
MD patients need effective therapy to improve their quality of life by ameliorating the dystrophic 
condition since these disorders can cause disability and death. Although the underlying 
molecular defects of MD have been known for many years, progress toward MD treatments is 
still far from the clinical stage. There are two major reasons for the difficulty in treating MD. 
One barrier is that skeletal muscle is the largest tissue of the body accounting for approximately 
40% of body mass. The other fact is that muscle myofibers have no ability to divide. However, 
the studies accumulated in the last few years have opened new avenues for all developing 
treatments. 
         Any effective treatment of MD must allow the therapeutic agent to reach most of the 
diseased muscles in the body. The development of useful therapeutic strategies also requires a 
rational understanding of dystrophic pathology. So far, therapeutic approaches in MD treatment 
can be divided into two categories: approaches that attempt to improve the dystrophic condition 
through pharmacologic therapy, and approaches that aim to overcome the gene defect by cell-
based therapy or gene therapy. Recent advances have uncovered various possible therapeutic 
strategies, from pharmacological interventions, cell-mediated therapy with newly isolated stem 
cells, to gene therapy. A combination of these approaches may successfully enhance their 
therapeutic effects. 
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1.1.4.1 Pharmacological therapy 
Several pharmacological strategies have been designed to restore, maintain, or improve muscle 
function and strength. Slowing the rate of muscle loss and increasing muscle mass could 
potentially be achieved with use of protease inhibitors and growth factors. Myofiber 
degeneration is followed by a persistent inflammation that induces macrophages to secrete tumor 
necrosis factor-alpha (TNF-α) and transforming growth factor beta (TGF-β), promoting muscle 
wasting and fibrosis in dystrophic muscle (82-87). Therefore, anti-inflammatory molecules have 
beneficial effects in delaying the pathogenic course of dystrophic muscle (88). 
         Glucocorticoids, such as prednisone and deflazacort, can delay the disease progression of 
DMD (89-91). Several studies show that glucocorticoid treatment in DMD boys can prolong 
independent ambulation for at least two years, slow the development of skeletal muscle defects, 
and delay the occurrence of respiratory and cardiac failure. These therapeutic benefits are due to 
their ability to preserve existing muscle fibers, to enhance myogenesis, and to suppress 
inflammatory responses. Unfortunately, these drugs have their side effects including decreased 
bone density and weight gain. In contrast to prednisone, deflazacort, the prednisone derivative, 
provides an effective alternative treatment with less severe side effects (92, 93). Besides the 
consideration of side effects, deflazacort has been shown to stimulate utrophin expression via the 
calaineurin/NFAT signaling pathway (94). The expression of utrophin can functionally 
compensate for dystrophin (95, 96).       
         The balance between muscle anabolic and catabolic processes is required for supporting 
normal muscle function. The fundamental principle has been recently applied to the new 
treatment of MD. It is suggested that stimulating anabolic processes can overcome, or slow 
muscle wasting in MD individuals since anabolic processes are able to proliferate and recruit the 
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muscle progenitor cells. This thought has been performed by the treatment of insulin growth 
factor 1 (IGF-1). IGF-1 acts as a potent anabolic agent in skeletal muscle and thus, it increases 
the synthesis of protein and nucleic acid as well as prohibits protein degradation. IGF-1 
treatment improved the muscle maximum force in laminin-deficient dy/dy mice and attenuated 
pathologic changes of muscle dystrophy in mdx mice (97, 98). Unlike IGF-1, myostatin is a 
negative regulator of muscle growth. When mdx mice were given neutralizing antibodies to 
myostatin, muscle mass and strength were increased (99).  
         Recent evidence has shown that the majority of the muscle protein breakdown relies on the 
ATP-ubiquitin-dependent pathway (100). Compared to healthy individuals, DMD and other 
neuromuscular disorders abnormally increase proteasomes and ubiquitin in dystrophic muscle 
(100). In mdx mice, the proteasome inhibitor approach has revealed its ability to restore the 
membrane localization of dystrophin-associated proteins by blocking the ubiquitin pathway 
(101). Several cytokines have been associated with anabolic effects on skeletal muscle. 
Interleukin-15 (IL-15) is identified as a highly expressed growth factor in skeletal muscle. 
Notably, IL-15 appeared to ameliorate muscle wasting in tumor-bearing rats via the inhibition of 
the ATP-ubiquitin-dependent pathway (102). This finding could make IL-15 as a potent 
treatment for the muscle wasting involved in MD.      
         About 5%~15% of DMD cases are caused by premature stop codon in the dystrophin gene. 
Interestingly, the use of gentamicin suppressed the stop codon and led to the expression of 
functional dystrophin offering some level of strength against damage in mdx mice (103). 
However, the long-term effect of gentamicin treatment is still required to be determined. Finally, 
several new treatments have been carried out. Muscle protein synthesis directly associates with 
free amino acid glutamine concentration. DMD patients with administration of L-glutamine 
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appeared to reduce protein breakdown (104). Other approaches, such as calcium channel 
blockers, growth hormone inhibitors, and vitamin E, have been proved unsuccessful in MD 
treatment. 
         So far, the use of steroids and anabolic agents still remains the only available treatment in 
humans and provides the improvement of dystrophy.  
1.1.4.2 Cell-based therapy 
Cell-based therapies are carried out by implantation of functionally healthy myogenic cells into 
dystrophic muscle. A cell-mediated approach potentially provides two beneficial actions in 
dystrophy. The normal or genetically corrected donor myogenic cells not only fuse with 
dystrophic myofibers to allow the expression of a therapeutic protein deficient in the diseased 
myofibers (105, 106), but also give rise to a source of muscle precursor cells in myopathic 
muscle (107-109). 
          A pilot study converted mdx myofibers from dystrophin-negative to dystrophin-positive by 
the injection of wild-type myoblasts in 1989 (110). This study faced several challenges when this 
approach was applied to human studies. First, the injected donor cells had very limited migratory 
capacity. Second, the donor myoblasts exhibited poor survival. Third, immune responses against 
delivered myoblasts or newly synthesized therapeutic protein were induced by transplantation. 
Ex vivo mediated-transfer has been developed to improve the efficiency of myoblast transfer. In 
this strategy, myoblasts isolated from DMD boys were genetically modified by transduction of 
the dystrophin gene and then they were reintroduced into the patient (111). The Ex vivo based 
approach revealed some level of improvement in myoblast transfer, but its ability to circumvent 
the host immune response still needed to be optimized.  
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         To resolve the lack of dispersion of donor cells in the host muscle, the use of blood-borne 
stem or progenitor cells might counteract this obstacle. Systemic delivery of circulating stem 
cells possessing myogenic potential is a feasible choice over myoblasts which remain in the area 
of injection. A successful report indicated that a fraction of bone marrow cells, referred to as side 
population (SP) cells, led to dystrophin expression in mdx mice after transplantation (112). In a 
related study, SP cells from a dystrophic mouse transduced with lentiviral vector expressing 
human micro-dystrophin were shown to express transgene in dystrophic myofibers following 
intravascular delivery (113). Recent findings have discovered that except SP cells, CD45 
negative cells, such as multipotent adult progenitors (MAPs) (114), mesoangioblasts (115), 
muscle-derived stem cells (116), and synovial membrane-derived mesenchymal stem cells (SM-
MSCs) (117), enable differentiation into skeletal myotubes in vitro and in vivo. In 
immunosuppressed mdx mice, human SM-MSCs not only restored the expression of dystrophin 
at the sarcolemma of muscle fibers, but also reduced central nucleation after local transplantation 
(118). The ability of human SM-MSCs to rescue systemic dystrophic myopathy via intravenous 
delivery has not been tested. 
         The extension of donor cell survival can be modulated by immunosuppressants. The use of 
tacrolimus (FK506) was efficient for the myoblast transplantation in monkeys, but it displayed 
long-term adverse effects (119). The development of immune tolerance is another potential 
application to reduce the immunogenicity of donor cells. Myoblasts expressing human 
lymphocyte antigen-G (HLA-G), a key mediator of maternal tolerance to the fetus, showed the 
resistance to cell lysis by alloreactive lymphocytes (120).    
         Currently, myoblast transplantation through intramuscular injection is the only cell-based 
therapy that has provided promising results at the site of injection in the non-human primate. The 
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next milestone should continue the attempt to achieve sufficient therapeutic effects systemically 
without immune complication. 
1.1.4.3 Gene therapy 
MDs are mostly caused by single-gene blemishes. Gene therapy amends a genetic defect by the 
replacement or modification of a gene. When transgenic mdx mice expressing full-length 
dystrophin displayed no sign of the myopathy (121), gene therapy seems to be a promising 
approach to restore proper muscle function by reintroduction of a well acting gene into 
dystrophic muscle. Development of gene therapy for DMD provides a model for pursuing 
genetic therapies in other types of dystrophies. 
         The simplest approach of gene therapy is the injection of naked plasmid DNA encoding 
dystrophin into muscle. In 1990, Jon Wolff and his colleagues proved that mouse skeletal muscle 
could uptake and express plasmid DNA via intramuscular administration (122). Although the 
plasmid DNA delivery held the long-term gene expression, the gene delivery efficiency of naked 
plasmid was very low following intramuscular injection (123). A possible reason for the 
inefficiency of plasmid DNA delivery would be due to nuclease activity in the body. However, 
the methods including in vivo electroporation and hydrodynamic vascular delivery have 
improved the efficiency of plasmid-based gene delivery over the last several years (124-126).  
         The use of viral vectors for gene delivery is an alternative approach to gene therapy. GFP 
expression of up to 50% of the muscle fibers at the site of injection can be achieved through 
lentiviral vector delivery (127). Because lentiviral vectors raise concerns about insertional 
oncogenesis and enveloped vector particles have less stability, most current studies have 
occupied nonenveloped adenovirus (Ad) or AAV for delivery of therapeutic gene.  
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         Early region 1 (E1)-deleted Ad vector was the first successful viral vector system to deliver 
a 6.3 kilobase pair (kbp) truncated dystrohin cDNA to skeletal muscle of mdx mice (128). 
However, this Ad vector caused a strong immune reaction to the expression of rest viral proteins 
(129). The Ad vector induced inflammatory process can exacerbate muscle weakness. In order to 
counteract problems of undesirable Ad vector immunogenicity, a newer generation of Ad vector, 
gutted (or helper-dependent) Ad vector, has been developed. Gutted vectors do not carry any 
viral coding sequence producing viral proteins and thus they can accommodate the full-length 
dystrophin cDNA. These helper-dependent Ad vectors expressing full-length dystrophin 
functionally corrected mdx muscle in adult mouse and induced a weaker immune response (130, 
131).  
         Compared to Ad vectors, AAV vectors have less immunological and inflammatory 
response in vivo and they are more efficient for transducing adult muscle fibers due to their 
smaller size (132, 133). The AAV genome capacity is only about 4.7 kilobases (kbs), so they can 
not deliver full-length dystrophin. To date, a truncated mini- or micro-dystrophin gene can be 
packaged in AAV capsid and the expression of mini-dystrophin via AAV delivery retains good 
functional rescue in transgenic mdx mice (134).  
         Exon skipping has recently been used to direct a restoration of the translational reading 
frame of the dystrophin mRNA. A 2’-O-methyl antisense oligonucleotide has been engineered 
by removing mutated exon from the mdx dystrophin mRNA in cultured primary muscle cells 
(135). Besides, an extended study was achieved by targeting the donor and acceptor sites of 
mutated exon 23 with a modified antisense U7 small nuclear (sn) RNA (136). The removal of 
mutated exon 23 on the dystrophin mRNA of mdx mice produced functional dystrophin at the 
physiological level and leaded to the correction of MD.     
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         Gene repair has been established by the utility of chimeric RNA/DNA oligonucleotides. 
These designed chimeric oligonucleotides are homologous to a targeted mutant gene and contain 
only one mismatched base. A binding between the chimeric oligonucleotide and the defective 
gene triggers the cell to repair the mutated gene based on the correct sequence of 
oligonucleotides. Rando et al. reported that RNA/DNA chimeric oligonucleotides mediate 
dystrophin expression at mdx muscles via the correction of a point mutation occurring in the 
dystrophin gene (137, 138).  
         Researchers have exploited a different method of gene therapy, the expression of “booster 
genes,” instead of replacement or modification of a defect gene. The delivery of booster genes 
tries to help muscle resist degeneration by alleviating the different damaging events. For 
example, expression of integrin α7, GalNac (N-acetyl galactosamine) transferase, or ADAM12 
(a disintegrin and metalloprotease), enhanced cell adhesion and muscle stability while dystrophin 
was missing (139-141). Mini-agrin expression promoted basement membrane formation in the 
absence of laminin α2 (142, 143). Overexpression of calpastatin reduced mdx muscle necrosis 
(144). Neuronal nitric oxide synthase (nNOS) expression showed anti-inflammation in mdx mice 
(145). Gene delivery of IGF-1, myostatin blockage, or ADAM12 accelerated muscle 
regeneration and decreased fibrosis (98, 99, 141). Gene transfer of an utrophin minigene 
prevented the dystrophic phenotype and restored DGC complex localization at the muscle 
membrane (146). Transgene-mediated utrophin upregulation is also an exciting avenue for MD 
gene therapy. 
         Investigators have explored a way to achieve functional restoration of dystrophic muscle 
and prevention of MD in human for years. Beyond doubt, the best approach is to deliver the 
therapeutic gene through the circulation. Like cell-based therapy, gene therapy faces a 
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formidable difficulty in systemic delivery. A study indicated that the coadministration of 
vascular endothelium growth factor (VEGF) with AAV6 vector reached the whole-body muscle 
transduction after systemic intravenous delivery (147). AAV8 also showed the persistent 
transduction of heart and skeletal muscle when injected intravenously (148). Unfortunately, both 
deliveries result in unwanted transduction in other tissues, such as the liver and gonads. This 
unspecific targeting causes serious concern about vector security and countable therapeutic 
effects in humans. To improve the safety and efficiency of gene therapy in clinical applications 
of MD, we ultimately need to develop a novel vector which specifically targets the heart and 
skeletal muscle without undesirable cell transduction and immunogenicity after systemic 
administration. 
1.2 Adeno-associated virus 
1.2.1 Discovery 
In the middle 1960’s, AAV was discovered as a contaminant of Ad preparations in the 
laboratories of Robert Atchison at University of Pittsburgh and Wallace Rowe at NIH. AAV 
virions were first characterized by electron microscopy during examination of human and simian 
Ad preparations (149-151). Immediately after AAV discovery, it was demonstrated that AAV 
infections have never been associated with any known diseases even though most humans have 
been exposed to AAV. Therefore, AAV did not receive much attention from virologists due to 
the absence of pathogenicity at the beginning.  
         By 1980, and in the early development of gene delivery for therapeutic applications, there 
were clear reasons to develop AAV vectors as gene transfer vehicles because AAV is not a 
pathogen and it appears to have a mechanism for persistence. To date, AAV has been regarded as 
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a dark horse among vector systems which are commonly developed for human gene therapy. 
Valuable data from preclinical and recent clinical evaluations have shown that the AAV vectors 
achieve the therapeutic effects in humans. 
         So far eleven AAV serotypes have been isolated. Among these serotypes, AAV serotype 2 
(AAV2) isolated from humans is the most extensively characterized serotype. The basic 
information of AAV biology mostly covers the studies done on AAV2.  
1.2.2 AAV genome 
AAV is a nonenveloped virus that has been assigned to the dependovirus genus of the parvovirus 
family. The AAV particle possesses a diameter about 22 nm and contains a linear single-stranded 
DNA genome of approximately 4.7 kbs with either plus or minus polarity. The AAV genome 
consists of two open reading frames (ORFs) termed rep and cap. The ends of the viral genome 
are flanked by the inverted terminal repeat sequences (ITRs). Viral transcripts produced from all 
promoters on the AAV genome have the same intron and they share a common polyadenylation 
signal.  
         The rep gene is transcribed from the p5 and p19 promoters (152). Both spliced and 
unspliced rep mRNAs are translated into four proteins. Rep proteins are non-structural proteins 
and they were originally thought to serve functions necessary for regulation of AAV promoters 
as well as for DNA replication of AAV. The p5 promoter directs expression of the larger rep 
proteins, Rep78 and Rep68. Rep78 is translated from the unspliced transcript while Rep68 is 
synthesized from the spliced mRNA. Rep78 and Rep68 can bind to the p5, p19, and p40 
promoters of viral genome to regulate the AAV gene expression (153). Besides, Rep78 and 
Rep68 are associated with helicase and ATPase activity to participate in DNA replication 
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process of AAV. Through the interaction of Rep78/68 with Rep-binding element (RBE) in AAV 
ITRs (154), Rep78 and Rep 68 introduce a nick at the terminal resolution site (trs) of ITR by 
their ATP-dependent DNA helicase activities. This nicking site provides a new priming 3’OH 
group to allow continuous DNA synthesis during AAV replication (155, 156). Rep78 and Rep 68 
are also involved in AAV genome integration into the AAVS1 site of human chromosome 19 
(157-159). The unspliced transcript from the p19 promoter produces Rep52 protein, and the 
spliced mRNA from the p19 promoter generates Rep40 protein. Rep52 and Rep40 are important 
for AAV package. The initial step of AAV encapsidation is operated by the interaction between 
preformed empty capsids and a complex of Rep78 or Rep68 with the/a viral genome. Thus, the 
helicase domains of capsid-occpuied Rep52 and Rep40 are responsible for transferring newly 
synthesized viral genomic DNA into empty particles via the pores created at the fivefold 
symmetry axes (160, 161). 
         The cap gene of AAV encodes three capsid proteins, VP1, VP2, and VP3, from transcripts 
initiating at the p40 promoter (162). Two distinct mRNAs are synthesized from the p40 promoter 
for cap protein translations. VP1 is translated from an AUG start codon on the 2.4-kb mRNA. 
VP2 and VP3 come from the same transcript, the 2.3-kb mRNA. Interestingly, VP2 uses a 
weaker ACG start codon for its protein synthesis, while VP3 employs the next available AUG 
codon for its production on the same mRNA. VP1, VP2, and VP3 proteins possess molecular 
masses of 87, 73, and 62 kDa, respectively. In purified virions, VP1, VP2, and VP3 have a molar 
ratio of 1:1:10. These capsid proteins share overlapping sequences and they only differ at their 
amino termini. VP3 is 65 residues less than VP2. Compared to VP2, VP1 is extended at its N 
terminus by 137 amino acids. It has been identified that VP1 contains a phospholipase A2 
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(PLA2) domain and this domain is essential for AAV infectivity. VP3 is also required for AAV 
production, but VP2 is totally negligible for efficient viral packaging and infection (163).        
         AAV ITR is 145 bp in length and locates at both ends of viral genome. The ITRs on AAV 
genome are only cis-acting elements necessary for viral DNA replication, packaging, host 
chromosomal integration, as well as provirus rescue of AAV. Although ITR is not essential for 
high yield of Rep and Cap expression during virus production, it has been indicated that ITR 
contains enhancer activity on AAV promoters. Each ITR consists of an outer 125-nucleotide 
palindrome and a 20-nucleotide internal sequence named the D sequence. The outer 125 bases of 
ITR form a “T”-shaped palindromic hairpin structure via self-complementarity (164). The 
sequence segments of “T”-shaped hairpin are represented as A, B, C and their reverse 
complementary segments are termed as A’, B’, C’. So the typical hairpin of each ITR at the ends 
of AAV genome is constructed as ABB’CC’A’-D in sequence order. The D sequence is appeared 
only once at each end of the viral genome and remains single-stranded. ITR serves as the origin 
of AAV DNA replication due to its ideal template-primer hairpin structure for cellular DNA 
polymerases. The D sequence is further divided into two sequence stretches. The 10-nucleotide 
area adjacent to the hairpin is required for viral replication, packaging, and rescue (165). The 
next 10-nucleotide region of D sequence contains the binding motif of the single-stranded D-
binding protein, a host protein FKBP52 (166). Phosphorylated FKBP52 interacting with the D 
sequence inhibits the conversion from single-stranded AAV (ssAAV) genome to the active 
double-stranded DNA state via the blocking of viral second-strand DNA synthesis (167).  
Moreover, there is a transcription initiator element in the D sequence. This element does not 
present any function in AAV life cycle. But it has been utilized as the basal promoter in the 
application of gene therapy (168). 
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1.2.3 AAV life cycle   
AAV is described as a “defective” virus because AAV typically requires coinfection with a 
helper virus in order to efficiently replicate in a host cell. The helper virus is usually Ad or 
herpes simplex virus 1 (HSV1) (169). The helper function can also be provided from vaccinia 
virus, cytomegalovirus (CMV), and human herpesvirus type 6 (170, 171). E1, E2A, E4, and VA 
proteins of Ad or HSV1 UL5, UL8, UL29, and UL52 genes are capable of providing the helper 
function for AAV replication (172, 173). It is presumed that the helper virus creates the proper 
cellular environment and it is not directly involved in AAV propagation. In the presence of a 
helper virus, AAV enters into the productive phase and results in the release of newly assembled 
AAV virions from cells upon helper virus-induced cell lysis. 
         In the absence of a helper virus, the AAV gene expression program is suppressed and viral 
latency ensues by the integration of the virus genome into human chromosome 19 (174). This is 
the reason that AAV establishes a persistent infection when AAVs infect mammalian cells alone. 
In addition, AAV genes integrated in the host genome can be activated to lead to the AAV Rep-
mediated excision of provirus DNA from cellular chromosome when a latently AAV infected 
cell has super-infection of a helper virus. Then, the rescued AAV provirus turns into the 
productive life cycle and completes AAV propagation. The introduction of the productive phase 
of AAV life cycle from a latent integrated provirus can also be observed by non-viral 
stimulations with a lower efficiency. The limited replication occurs in a latently infected cell 
after ultraviolet irradiation, heat shock, carcinogens, or treatment of cells with genotoxic agents 
such as hydroxyureas (170, 175, 176).     
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1.2.4 AAV receptor 
A successful AAV infection initiates from the attachment of a virion to the cell surface followed 
by viral absorption, intracellular trafficking, nuclear transport, and localization or replication of 
the viral genome in the cell nucleus. AAV infection relies on the expression of a specific cellular 
receptor allowing viral binding and entry into the target cell. The primary attachment receptor for 
AAV2 is identified to be cellular membrane-associated heparan sulfate proteoglycan (HSPG) 
and AAV2 transduction is efficiently competed with heparin (177). In addition, AAV2 has also 
been determined to utilize αVβ5 integrin, fibroblast growth factor receptor-1 (FGFR1), and 
hepatocyte growth factor receptor (c-Met) as coreceptors providing cellular internalization (178-
180). More recently, α5β1 integrin has been shown to be an alternative coreceptor of AAV2 in 
human embryonic kidney 293 cells (HEK 293 cell) which lack the expression of αVβ5 integrin 
(181). AAV3 shows the ability to bind heparin, but the AAV3 capsid residues involved in 
heparin binding remain undetermined.   
         The cellular receptor for AAV4 and AAV5 is identified to be sialic acids with different 
linkage forms. AAV4 uses O-linked sialic acid, α2,3 O-linked sialic acid, for viral entry while 
AAV5 binds to N-linked sialic acids, α2,3 N-linked sialic acid and α2,6 N-linked sialic acid, 
during viral infection (182, 183). AAV5 also utilizes platelet-derived growth factor receptor 
(PDGFR) to mediate the viral binding and internalization (184). 
         According to the viral capsid sequence, AAV1 differs from AAV6 by only six amino acids. 
So it is not surprising that both viruses share some common cellular receptors or that they 
interact with the same receptor for viral transduction. By using cell-based assays, it has been 
shown that α2,3 and α2,6 sialic acids appeared on N-linked glycoproteins facilitate AAV1 and 
AAV6 infections (185). However, AAV6 has more efficient liver transduction compared to 
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AAV1 (186). This phenomenon gives rise to the question of how this difference could exist if 
AAV1 and AAV6 use the same receptors. Wu et al. showed that AAV6 transduction relies on 
sialic acid more than AAV1 although the binding ability of AAV6 to sialic acid is not better than 
that of AAV1 (185).  
         AAV8 currently appears to be a powerful gene delivery vector because it can efficiently 
cross the blood vessel barrier. In a recent study, the 37/67 kDa laminin receptor (LamR) is 
demonstrated to be a cellular receptor for AAV8 by conducting a yeast two-hybrid screen (187). 
Two separate AAV8 capsid subdomains have been proved to mediate the LamR binding. The 
overexpression of LamR or the siRNA–mediated LamR inhibition determined that LamR is also 
important for the transductions of AAV2, AAV3, and AAV9.  
1.2.5 AAV intracellular trafficking 
The increasing development of AAV as a gene therapy vector has expedited the discovery of 
events affecting the efficiency of AAV transduction. In general, the biological process of AAV 
transduction can be divided into seven stages. These stages include: 1) viral binding to cell 
surface through the interaction with the cellular receptor and coreceptor, 2) receptor-mediated 
endocytosis of virus for viral entry, 3) viral trafficking via the endosomal compartment, 4) viral 
escape from endosome, 5) viral nuclear translocation, 6) virus uncoating, and 7) viral genome 
conversion from a single-stranded to a double-stranded molecule capable of gene expression. 
Except the binding affinity of the viral particle to the cell membrane, the pace of viral uncoating, 
and the viral genome conversion, the intracellular trafficking is also a rate-limiting factor in 
AAV transduction (188). The intracellular trafficking of AAVs is used to describe a process 
involving the movement of virus from cellular membrane to the cell nucleus (stage 3 to stage 5) 
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and it is influenced by cell types. At present, the knowledge of AAV trafficking is based on 
AAV2 and AAV5. The realization of intracellular trafficking among other serotypes is relatively 
limited.  
         Receptor-mediated endocytosis controlling AAV cell entry has been shown in AAV2 and 
AAV5. For AAV2, it was indicated that virus binding to HSPG enters cells through calthrin-
coated pits in a dynamin-dependent manner. The introduction of a mutated dynamin led to the 
decrease of AAV2 transduction (189). AAV5 uses a different primary attachment receptor; 
however, it also conducts viral endocytosis via clathrin-coated pits (190). In addition, AAV 
binding to cell receptors can initiate intracellular signaling pathways and subsequently stimulate 
receptor-mediated endocytosis. For example, the binding of AAV2 to the integrin coreceptor 
during internalization activates Rac1, a small GTP-binding protein. The activation of Rac1 
results in triggering the phosphatidylinositol-3 kinase (PI3K) pathway that facilitates the 
rearrangement of cellular microtubules and microfilaments for movement of AAV2 particles to 
the nucleus (191). 
         Rab proteins belong to a family of small GTPases that are involved in the process of 
endosomal budding, sorting, movement, and fusion in the cell. Following endocytosis, AAV 
virus appears to enter into early endosome which is characterized by containing the small 
GTPase Rab5. At low multiplicities of infection (MOI) of recombinant AAV2 (rAAV2), Rab5 
early endosome is predominantly routed to Rab7 late endosome (192). In contrast, rAAV2 at 
high MOI preferentially traffics from Rab5 early endosomal compartment to perinuclear 
recycling endosome (PNRE), a Rab11-positive compartment. The late endosomal compartment 
can be further transported to either the lysosome or the trans-Golgi. Rab7 directs the movement 
of late endosome to the lysosome while Rab9 mediates the late endosomal movement to the 
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trans-Golgi (193). Similarly, PNRE can be translocated in the trans-Golgi through a Rab11 
dependent mechanism (194). 
         Several studies have proven that rAAV2 transduction is remarkably decreased when 
acidification of the enosomal compartment is impeded by the treatment of bafilomycin A1 (195). 
This indicates that a low endosomal pH is required for rAAV2 to escape from the endosome and 
is likely to promote conformational changes of key viral capsid proteins essential for AAV 
endosomal release and nuclear translocation. Certainly, the inactivating point mutations of the 
PLA2 domain of AAV2 VP1 do not hamper viral capsid assembly, packaging, and cell entry, but 
decrease the amount of gene expression (196). Therefore, PLA2 domain in VP1 may play a role 
for the viral release from the endosome and the transfer of the viral DNA to the nucleus. Another 
interesting finding of AAV is that proteasome inhibitors appear to enhance the viral transduction 
of AAV2 and AAV5. The enhanced viral transduction is not due to the blocking of viral genome 
degradation or the modulation of second-stranded genome synthesis. The inhibition of 
proteasome increases the nuclear uptake of viruses and viral gene expression in different cell 
systems (197, 198). Since both rAAV2 and rAAV5 capsids are able to be modified by 
ubiquitination in vivo and in vitro (199) and the blocking of proteasome activity increases capsid 
ubiquitination following the enhanced viral transduction, it suggests that the ubiquitin-
proteasome pathway has a significant role in regulating capsid disassociation and nuclear 
transport of AAV during AAV infection. The priming of AAV capsid for ubiquitination may be 
taken inside the endosomes. 
         The intracellular processes underlying viral uncoating and nuclear translocation are mostly 
unclear. It is presumed that AAV particles enable to be translocated into the nucleus prior to 
uncoating because florescent-labeled AAV virions were observed in the nucleus (200). Since the 
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diameter of an AAV particle is almost the same size as the nuclear pore, the nuclear translocation 
of intact virion may be due to diffusion. Unfortunately, the nuclear transport of intact AAV virus 
presents a slow and inefficient process, so that most AAV virions accumulate in a perinuclear 
area. Therefore, it gives rise to the hypothesis that AAV can also become uncoated before or 
during nuclear translocation. 
1.2.6 AAV capsid structure 
Tissue tropism and immunogenicity of AAV gene transfer vector are determined by specific 
interactions between viral capsid and host cellular components. Therefore, an understanding of 
the structural and functional correspondence of AAV capsid is required for engineering AAV 
tissue tropism in gene delivery as well as designing the nonimmunogenic vector in long-term 
gene expression. 
         To date, several AAV capsid structures have been solved by using X-ray crystallography or 
cryoelectron microscopy (cryo-EM) coupling image reconstruction. The atomic structure of 
AAV2 has been demonstrated at a 3 Å resolution by X-ray crystallography (201). The capsid 
structures of AAV4 and AAV5 have been determined by using cryo-EM and image 
reconstruction at a resolution of 13 Å and 16Å, separately (202, 203). Preliminary X-ray 
crystallographic analysis of AAV8 capsid has also been reported recently (204). AAV virus can 
generate VP1, VP2, and VP3 proteins as capsid subunits. The common feature of AAV capsid 
structures among all AAV serotypes is that the viral shell comprises 60 capsid protein subunits 
arranged with T=1 icosahedral symmetry. In all AAV viruses, the capsid protein subunit 
possesses a highly conserved β-barrel core comprised of eight strands from two antiparallel β-
sheets. The β-barrel core is on the inner surface of the viral capsid. In contrast to the strands of 
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the β-barrel, the large interstrand loops located between the strands of the β-barrel have quite 
variable structures in the different AAV serotypes and are the regions responsible for antibody 
recognition and cellular receptor binding since these loops can be exposed on AAV surface. For 
example, the most prominent feature of AAV2 surface topology is the cluster of the threefold-
proximal peaks. Each of threefold-related peaks on the capsid is an association of loops from two 
neighboring subunits. Mutations near the positively charged side of each peak affected the HSPG 
binding of AAV2. In addition, the basic patches on AAV2 threefold axis peaks controlling 
HSPG binding are missing from AAV5. This shows that the variety of AAV capsid surface 
structures direct specific cellular receptor binding and results in AAV’s unique tissue tropism.  
1.2.7 rAAV production in gene therapy 
The AAV ITRs are only cis-acting elements required for vector production and transduction. The 
AAV coding sequences can be replaced by the transgene of interest because both the rep and cap 
gene products together with helper virus proteins can be supplied in trans to manufacture 
infectious rAAV virion as a therapeutic tool. The production of rAAV initially requires the use 
of Ad virus. Undoubtedly, it raises safety concerns about incomplete elimination of Ad viral 
activity and host immune response against Ad capsid proteins existing in rAAV preparation even 
after the heat inactivation of rAAV stocks for human treatment. Thus, the present method for 
rAAV production makes use of a three-component plasmid system (205). The three plasmids in 
this AAV production system are a) AAV plasmid vector bearing the desired transgene flanked by 
AAV ITRs, b) AAV helper plasmid offering AAV Cap and Rep proteins in trans, and c) Ad 
helper plasmid providing Ad E2, E4, and VA proteins necessary for efficient AAV genome 
replication and gene expression. The cotransfection of these three plasmids into HEK 293 cells 
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stably expressing Ad E1A and E1B proteins results in the production of rAAV vectors. In the 
presence of helper functions from supplied Ad genes, the rAAV genome is submitted to the lytic 
productive phase of wild-type AAV life cycle by being rescued from the plasmid backbone. The 
rescued rAAV genome is then replicated and packaged into preformed empty capsid as single-
stranded DNA molecule. After contransfecion, the virus can be purified by CsCl density gradient 
ultracentrifugation or through various chromatographies. Although the three-component plasmid 
system produces the Ad-free rAAV stocks without heat inactivation and it is perhaps the most 
robust and versatile way for vector preparation, this method is unwieldy for large-scale vector 
production in clinical human gene therapy. The infection of stable AAV Rep and Cap producing 
cells with adenovirus carrying rAAV vector genome has presented a way for scale-up (206). 
Furthermore, the transduction of proviral cell lines with Ad or HSV1 containing a Rep and Cap 
expression cassette has shown high-titer rAAV production (207, 208). However, these 
approaches for increasing rAAV titers still require the complete elimination of the helper virus 
during viral stock preparations. So recent work in the development of baculovirus expression 
system for rAAV production in insect SF9 cells has shown promise for future large-scale 
production (209). The helper functions from Ad can be provided by baculovirus. However, the 
baculovirus helpers tend to have passage-dependent loss-of-function deletions leading to a 
decrease of rAAV titer (210). The modification of AAV rep gene in baculoviral helpers 
increased the passaging stability of baculovirus vector system. Nevertheless, the use of a 
baculovirus system at a passage number of two or less is suggested for sufficient large-scale 
rAAV production.   
         When designing and cloning a rAAV vector plasmid, it should be considered that the two 
AAV ITRs occupy approximately 300 bps. To ensure efficient rAAV encapsidation, the 
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transgene expression cassette should not be more than 4.5 kbps. This small packaging capacity of 
AAV particles becomes one of the major limitations in rAAV vector applications. To overcome 
the limited packaging capacity of AAV, a strategy has been developed based on the 
heterodmerization of two AAV vectors through the formation of concatamers from either 
integrated or episomal viral DNA (211). Therefore, a large gene can be split and packaged into 
two separate rAAV vectors. One vector contains a promoter, the 5’ portion of the transgene, and 
a splice donor sequence (SD) while the second vector carries a splice acceptor sequence (SA), 
the 3’ portion of the transgene, and a poly A sequence. The coinfection of these two AAV 
vectors into target cells produces head-to-tail heterodimers via intermolecular recombination at 
the identical sequence homology of the ITRs. Rejoining the split gene into one continuous DNA 
molecule then occurs. The presence of SD and SA in this united DNA molecule allows the fused 
ITR sequence to be removed from synthesized mRNA and subsequently saves the expression of 
the intact desired protein. Although this split delivery strategy permits expression of almost 
double-sized transgenes in rAAV-mediated gene transfer, the efficiency of head-to-tail 
heterodimerization is consistently low. Finally, a study showed that the ratio of head-to-tail 
recombination could be efficiently increased by using vectors carrying hybrid ITRs of AAV 
serotype 2 and 5 (212).  
         The conversion from single-stranded genome to double-stranded DNA molecule, 
conducting by host-cell DNA synthesis machinery, is one of the main limiting steps for the 
efficiency of rAAV transduction. To date, self-complementary AAV (scAAV) vectors, and 
named double-stranded AAV (dsAAV) vectors, have been generated to bypass the rate-limiting 
step of second strand synthesis. Several designs showed deletion of D sequence or mutation of 
the trs site of one ITR produces high percentages of scAAV vectors (213, 214). The scAAV 
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vectors can achieve more rapid and efficient gene expression than ssAAV does. The counterpart 
to this enhanced transduction efficiency is an even more limited packaging capacity retaining 
about 2.3 kbps. The small therapeutic agents, such as antisense oligonucleotide and siRNA, are 
suitable for scAAV gene delivery. It is worth mentioning that this modified scAAV vector may 
make poorly AAV-transduced tissues more eligible for rAAV gene therapy. 
         Tissue-specific transgene expression is considered as the basic requirement for secure 
clinical applications in humans. Since rAAV vectors have a broad tissue tropism, the organ-
restricted transgene expression has been managed by the use of a tissue-specific promoter. The 
advantages of employing a tissue-specific promoter are the alleviation of immune response and 
the prolonging of transgene expression. As described, substitution of an MCK 
promoter/enhancer for a ubiquitous CMV promoter/enhancer in a rAAV vector producing γ-
sarcoglycan mitigated the immune response and enhanced levels of transgene expression in γ-
sarcoglycan-deficient mice (215). It suggested that a tissue-specific promoter minimizes immune 
response due to its avoidance of non-specific transgene expression in antigen-presenting cells 
(APCs). Although natural muscle-specific promoters generally diminish levels of transgene 
expression compared to non-specific viral promoters, such as CMV promoter, efforts have been 
made to enhance the strength of muscle-specific promoters by combinations of several myogenic 
regulatory elements. Several synthetic promoters containing E-box, MFE-2, TEF-1 or SRE 
myogenic regulatory cis-elements have been characterized to possess transcriptional potencies 
exceed those of natural myogenic promoters and viral gene promoters in muscle.   
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1.2.8 rAAV integration 
The preferred site for wild-type AAV integration is located on human chromosome 19q13.3-qter, 
named AAVS1. Rep78 and Rep 68 have the ability to bridge the interaction between the wild-
type AAV ITR and AAVS1 site on chromosome. Cellular high mobility group chromosomal 
protein 1 (HMG-1) has been proved to stimulate AAV Rep activity at low Rep concentration 
when AAV infection lacks the helper virus. The binding of HMG-1 to Rep protein may promote 
Rep-mediated site-specific chromosome integration by increasing Rep ATPase activity (216). 
However, it is not surprising that rAAV vectors display a different integration pattern on host 
DNA since rAAV genomes, only composed of AAV ITRs and transgene, do not encode Rep 
protein.  
         After rAAV genomes successfully translocate into the nucleus following infection, single-
stranded rAAV DNA needs to be transformed into a transcriptionally functional double-stranded 
template in order to express transgene. Duplex rAAV DNA molecules can then form circular 
episomes or linear concatemers. These extrachromosomal double-stranded DNA forms are 
transcription-competent agents. An interesting work has been postulated that free double-
stranded rAAV genomic ends are substrates for the cellular DNA repair machinery (217). The 
involved cellular double-stranded break repair machinery dedicates to remove free ended DNA 
molecule through non-homologous end-joining (NHEJ). A complex containing DNA-dependent 
protein kinase (DNA-PK) from this repair machinery regulates the balance between linear versus 
circular forms of double-stranded rAAV genomes. This regulation might be mediated by the 
binding of DNA-PK complex to linear rAAV DNA. Taken together, these results predict that 
free ended double-stranded rAAV genomes can be processed to not only circular episomes but 
also integrated proviruses due to cellular DNA repair systems responsible for cleanness of free 
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ended duplex DNA. As expected, subsequent study has shown that rAAV vectors appear to 
randomly integrate at chromosomal double-strand breaks. (218). Furthermore, rAAV vectors 
integrate at the existing chromosome breakage sites rather than self-causing breaks. The 
integration rate of double-stranded rAAV genomes is about 10% in the liver (219). The emerging 
consensus is that rAAV vectors generally persist as non-integrated episomes and they integrate at 
only low frequencies. 
         Chromosomal integration of rAAV vector DNA is a double-edged sword. It provides a 
foundation for persistent transgene expression over the long-term. On the other hand, it raises the 
safety issue about insertional mutagenesis. Because rAAV vectors do not create sites for 
chromosomal integration, concerns about insertional oncogensis for rAAV vectors are much less 
than those for lentiviral vectors. Recent research has shed some light on this issue; by examining 
the tumor formation in rAAV-treated mice, Bell et al. has determined that rAAV vectors do not 
have tumorigenic properties in a large-scale study (220).         
1.2.9 Immune responses to rAAV  
rAAV-mediated gene delivery can be limited by host humoral and cell-mediated immune 
responses against viral vector. Since rAAV vectors do not carry any viral genes, the primary 
target of the immune response is the viral capsid of vector particles. Several works have 
determined that the neutralizing antibodies against rAAV capsids are generated and could cause 
the failure of rAAV readministration in gene delivery. Interestingly, a study has revealed that 
over 80% of normal human subjects are seropositive for AAV antibody and 18% of them have 
neutralizing antibody. Because humans are natural hosts for AAV, the presence of pre-existing 
neutralizing antibodies may severely impair the application of rAAV in human gene therapy 
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(221). Mechanisms for antibody-triggered neutralization of viral infection include aggregation of 
viral particles, induction of capsid conformational changes, interruption of cellular receptor 
attachment, and inhibition of viral uncoating. As mentioned, the large loop insertions between 
the strands of the capsid β-barrel core constitute the majority of the capsid surface and are 
responsible for the interaction with antibodies. Compared to unmodified AAV2, AAV2 capsid 
mutants harboring peptide insertions in surface exposed loop regions have been shown to reduce 
up to 70% the affinity for AAV antibodies in human serum samples (222). Although the 
homology of amino acid sequence between AAV2 and AAV8 capsids is up to 83%, it has been 
proposed that AAV8 may have less concern about its preexisting immunity in humans. Because 
AAV8 is originally isolated from nonhuman primates, it dose not have prevalence in humans. 
         Extensive investigation into rAAV directed cytotoxic T lymphocyte (CTL) response has 
shown that the cellular immune response to rAAV vector is also dependent on AAV capsid. 
Specific T-cell responses to the capsid of rAAV2 vectors have been associated with liver toxicity 
in human gene therapy trial of hemophilia B (223). A recent work clearly demonstrated that 
AAV2 capsid elicits T-cell response against capsid, and AAV8 does not lead to activation of 
capsid-specific T cells in mice and cynomolgus macaques (224). 
         Notwithstanding the existence of rAAV capsid-induced immune response in human gene 
therapy, this obstacle may be overcome by the use of alternative serotypes and selective 
modifications of rAAV capsid protein. In practical applications, the transgene product of rAAV 
sometimes may act as an immunogenic antigen. This immune complication depends on the route 
of administration, the status of target tissue, and the nature of transgene product. The immune 
response derived from transgene expression can be adjusted by alteration of transgene epitopes 
without losing the physiological function of the delivered gene. 
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1.3 Engineering AAV tropisms 
The success of rAAV-mediated gene delivery in humans is associated with efficient tissue-
specific transgene expression. Except deployment of tissue-specific promoters, cell-restricted 
transgene expressions require the ability of the vector to bind to the desired target cells. In the 
past years, a number of AAV serotypes and over 100 AAV variants have been isolated from 
cultured Ad stocks, human tissues, and nonhuman primate sources. The benefits of diverse AAV 
serotypes in human gene therapy include the potential to evade preexisting immune responses 
and the ideal targeting due to their variety of native tropisms. The mechanism underlying diverse 
tissue tropisms of AAV serotypes is primarily associated with the usage of different cellular 
receptors.  
         Despite of AAV5, AA1 to AAV6 were found as contaminants in laboratory Ad stocks at 
the beginning. AAV5 was identified from a human penile condylomatous wart (225). 
Particularly, AAV2 and AAV3 are believed to originate from human due to their prevalence of 
neutralizing antibodies in humans (226). On the contrary, AAV4 appears to stem from monkeys 
because antibodies against AAV4 are present in nonhuman primates (227). The origin of AAV1 
remains unclear since AAV1 antibodies have been found in monkeys and AAV1 genomes have 
been discovered in human tissues (228). In theory, AAV6 is considered as a hybrid between 
AAV1 and AAV2. AAV6 left ITR and p5 promoter sequences are almost identical to those of 
AAV2 and the rest of AAV6 genome displays a similar composition to that of AAV1 (229). 
AAV 7 and AAV8 have been identified as originating in monkeys by a novel PCR-based 
strategy (230). By using the same PCR-spanning method, AAV9 is isolated from human tissues 
(228) while AAV10 and AAV11 have recently been confirmed to come from cynomolgus 
monkeys (231). AAV DNAs are not only isolated from primates but also are found in other 
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species, such as snakes, horses, cows, goats, chickens, and lizards. Among these AAV strains, 
avian and bovine AAVs have contributed to gene delivery studies (232, 233).  
         The different AAV serotypes reveal sequence variation within the capsid domain, which is 
responsible for host ranges and tissue tropism among the serotypes. In general, each AAV 
serotype has its preferential tropism when delivered locally. Gene transfer with AAV2 vectors in 
the central nervous system (CNS) shows efficient, non-toxic and long-time transgene expression 
(234). Compared to AAV2, AAV5 results in a more widespread infection in the brain (235, 236). 
While AAV5 and AAV4 are the best serotypes for retina infection, AAV1, 5, and 6 hold 
significant advantages over AAV2 for gene therapy in airway epithelial cells (237, 238). AAV 8 
is the most efficient vector in liver and pancreas targetings (230, 239, 240). However, AAV3 has 
not been found to offer noticable advantages in gene delivery. AAV9 has appeared to transduce 
murine lung and skeletal muscle better than AAV8 (228). AAV10 and AAV11 are used for gene 
delivery in individuals having a preexisting immunity to AAV2. 
         In muscular transduction, AAV1 and AAV6 show much more efficient gene deliveries in 
skeletal muscle and in cardiomyocytes compared to other AAV serotypes (241, 242). AAV7 
vector has an efficiency of gene transfer in skeletal muscle equivalent to that demonstrated by 
AAV1 (230).   
         However, all AAV serotypes result predominantly in transduction of the liver and display 
their tropisms in a wide range of tissue types with much lower efficiency after systemic delivery. 
It makes AAV difficult to perform efficient gene delivery specifically to certain tissues, which 
are either embedded in the deep places of body or distributed throughout the whole body, 
without invasive procedures. Thus, the purpose of creating new AAV vectors is to enable the 
transfer of therapeutic genes into cell types which are poorly transduced by current AAV vectors 
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and restrict AAV tropism to specific tissues via desired systemic delivery. So far, several 
outstanding approaches have been explored to manipulate the endogenous tissue tropisms of 
AAV vectors. The following methods have been developed to engineer novel tropisms derived 
from different AAV serotypes.  
1.3.1 Ligand-directed targeting  
Ligand-directed targeting of gene delivery rAAV vectors is a method to insert receptor-targeting 
peptides into viral capsids for achieving the proper surface display of ligand in presentation of 
the ligand to its receptor. Specific tissue-restricted transgene delivery is an important goal of 
gene therapy due to some critical considerations. First, current AAV vectors can be inefficient in 
acquiring entrance to the cell types needing treatment. Second, therapeutic transgenes may be 
harmful if delivered into unintended tissues. Based on these concerns, ligand-directed targeting 
provides the potential advantage of improving the safety and efficacy of gene transfer via rAAV 
treatment. 
         Phage display peptide libraries have been widely used to isolate ligands binding to desired 
cell types. At present, several groups have successfully redirected AAV targeting by 
incorporating the specific peptide identified by phage display into AAV capsid. For example, 
Work et al. identified peptides homing to the lung and brain by in vivo phage display from rats 
and then inserted these isolated targeting peptides after position 587 in the AAV2 capsid to 
retarget virus to the expected organs in a preferential manner (243). Although such incorporation 
of peptides isolated by phage display into the AAV capsid can be an ideal approach for specific 
gene delivery, the peptide conformation may be changed in viral capsid protein context and thus, 
the specific ligand-receptor interaction may be lost or diminished. The insertion of peptides 
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selected by phage display into AAV capsid may also interrupt functions necessary for the viral 
life cycle in viral production and could prohibit producing sufficient viral titers required for gene 
therapy. In order to counteract these limitations, Müller et al. selected appropriate ligand-inserted 
AAV mutants from a large library presenting random peptides at position 588 in the viral capsid 
(244). This successful work allows us to efficiently select ligand-displayed rAAV clones for 
high-affinity targeting to a specific receptor. 
1.3.2 Combinatorial AAV library 
Library-based approaches through DNA shuffling or error-prone polymerase chain reaction 
(PCR) are powerful ways to generate vector diversity for directed evolution. DNA shuffling, also 
named in vitro recombination involves digesting a set of functionally related genes with DNase I 
to a pool of random DNA fragments. These DNA fragments then can be reassembled into a full-
length gene by repeated annealing cycles in the presence of DNA polymerase. This reaction 
promotes the fragments to prime each other depending on sequence homology. Therefore, 
recombination takes place when fragments from one copy of a gene prime on another copy to 
cause template switching (245). This recombination strategy intends to extend the diversity of a 
library for evolution processes. Similarly, error-prone PCR technique is able to produce 
extensive vector variety for the selection of evolution. However, the error-prone PCR creates a 
library of mutants with random point mutations by PCR-based mutagenesis of a start sequence 
(246). Moreover, DNA shuffling and error-prone PCR can be combined to provide a large viral 
library diversity on specific purpose. Reiterative cycles of shuffling and controllable mutagenesis 
rate of error-prone PCR followed by screening or selection has proved to be a useful approach 
for the evolution of single-gene products with enhanced activity. 
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         More recently, a study has generated an AAV library on AAV2 cap gene with error-prone 
PCR-based mutagenesis and a staggered extension process analogous to DNA shuffling (247). 
Novel AAV2 variants with different heparin sulfate-binding affinities were identified by 
subjecting the viral library to heparin affinity column chromatography. Neutralizing-antibody 
escape clones were isolated by selection and amplification of infectious mutants in the presence 
of antiserum against wild-type AAV2 capsid. Furthermore, Perabo et al. have exploited error-
prone PCR to efficiently obtain the selected AAV vectors that escape neutralization by human 
antibodies (248).  
         The generation of AAV libraries with enhanced diversity for further directed evolution is 
not only to acquire novel tissue-specific AAV tropism, but also to enable mapping the structural 
and functional capsid domains of native targetings on various serotypes.     
1.3.3 Chimeric AAV vectors 
Chimeric vectors refer to the AAV virions composed of capsid proteins with domain or amino 
acid swapping between different serotypes. Rational swapping and marker rescue strategies have 
been involved in the production of chimeric rAAV vectors with different cellular receptor 
binding affinity. Domain swapping implies the transfer of specific capsid protein domains from 
one serotype to similar regions on another serotype. The swapped capsid domains range from 
single to multiple amino acids and can be surface loops or specific residues of viral particles. 
This strategy can provide vital information to identify capsid regions which are determinants for 
driving tissue tropism. By using domain swapping, a study has identified that the residue 350-
430 region of AAV1 VP1 capsid protein is critical for AAV1 muscle tropism (249). 
Nevertheless, it has been noticed that simply swapping domains may not always make chimeric 
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vectors gain desired specific tropism. For example, substitution of the heparin-binding motif 
from AAV2 onto a similar region of AAV5 capsid protein generated chimeric viral particles at 
good yields and conferred heparin-sulfate binding ability to these newly produced chimeric 
vectors. However, the resultant chimeric viruses were noninfectious on cells normally 
susceptible for AAV2 transduction (250). 
         The marker rescue approach is developed to take advantage of the sequence homology of 
cap gene between AAV serotypes for serving as crossover points for recombination initiated by 
cellular machinery (251). The recombination of cap sequences can lead to the rescue of 
infectious or targeted phenotypes in generated AAV mutants via directed selection of functional 
capsid domains assembled into mutated viable virions. A work has demonstrated that three 
AAV2 capsid mutant sequences identified as noninfectious and unable to bind heparin are 
rescued after cotransfection with AAV3 capsid DNA sequences.  
         Domain swapping and marker rescue techniques hold tremendous potential for the 
generation of chimeric rAAV vectors with newly acquired tropisms. Besides, these strategies can 
also contribute to establish structure-function correlates of AAV serotype capsids along with 
crystal structure data.  
1.3.4 Mosaic AAV vectors 
Mosaic AAV vectors can be defined as capsid structures composed of mixtures of complete 
capsid proteins from different serotypes or wild type and mutant capsid proteins from the same 
serotype. Theoretically, the ratio of capsid subunits from various sources or different serotypes in 
mosaic virions generally reflects the input ratio of cotransfected plasmids carrying different cap 
genes during viral production. Recently, Rabinowitz et al. manufactured a panel of mosaic 
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vectors by the transfection of pairwise combinations of AAV serotype 1 to 5 cap-expressing 
plasmids at several input ratio (252). Interestingly, mosaic viruses composed of AAV3 and 
AAV5 capsid mixtures at the 3:1 ratio exhibited duality in receptor binding. This AAV3-AAV5 
mosaic vectors displayed a phenotype combination from their parental viruses, AAV3 and 
AAV5, so they not only bind to heparin sulfate but also interact with mucin. In this method, new 
properties different from either parental virus have also been observed in some “cross-dressed” 
AAV virions. As described, AAV1 and AAV2 do not transduce Chinese hamster ovary K1 cells 
(CHO K1) efficiently in culture. Nevertheless, mosaic AAV1/2 virus, generated by transfection 
of AAV1 and AAV2 capsid protein-expressing constructs at a ratio of 1:3, exhibited dramatically 
increased transduction in CHO K1 cells. The new viral property derived from generated mosaic 
AAV vectors may be due to alterations in cellular receptor usage and intracellular trafficking of 
mosaic AAV1/2 virions in CHO K1 cells.  
         The mosaic approach may also furnish insight into capsid assembly in AAV biology. The 
generation of mosaic virions supplying combinations of AAV1 and AAV2 capsids all led to 
virion production at high titer, whereas mixing of AAV5 capsid subunits with other AAV 
serotypes displayed viral yields at moderate titers. Increase of AAV4 capsid subunits in the 
combination of other serotype capsids provided the lowest yields of mosaic viruses (252). These 
outcomes emphasize the importance of capsid subunit compatibility in viral assembly of hybrid 
virions for creating new tropisms. 
         By involving altered cellular receptor usage, mosaic strategies are a useful tool to generate 
novel tissue-specific tropism in a simple way. The unique advantage of this mosaic application is 
that it is able to combine selected characteristics from various capsid subunit sources that 
synergistically contribute to synthesize a novel tropism.   
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1.3.5 Two-component system 
The two-component system utilizes a bifunctional adaptor or bridging molecule that binds to 
AAV vectors and interacts with a target cellular receptor. In contrast to ligand-directed targeting, 
this method does not change the sequence of the cap genes nor does it force serious constraints 
on the size or types of used ligands.  
         The use of a two-component system to target AAV2 to a nonpermissive cell line has been 
carried out (253). A bispecific F(ab’γ)2 antibody was constituted with the binding specificity for 
AAV2 virion and the cell surface receptor αIIbβ3 integrin. This bispecific antibody mediated a 
novel interaction between AAV2 vector and the cellular receptor αIIbβ3 integrin expressed on the 
nonpermissive human megakaryocytes. Although this technique successfully directed AAV2 
vectors to interact with integrin and epidermal growth factor (EGF) in vitro (254), the stability of 
these conjugated vectors in in vivo targeting remains to be determined.  
         Two-component systems do not require information about the crystal structure of AAV 
capsids or capsid surface-displayed domains, but they involve in constructing the bispecific 
molecules and the determination of cell-specific receptors that mediate viral attachment and 
internalization. The potential of this strategy is limited in that the inclusion of the additional 
protein adaptor may raise the number of hurdles in the transfer of the two-component system into 
clinical and commercial applications.  
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1.4 Specific aims  
Non-viral and viral vectors can accomplish gene delivery to the targeted tissues. Among these 
vectors, AAV has been emerged as a powerful vector for gene transfer due to its 
nonpathogenicity and long-term gene expression. Although recombinant AAV vectors can 
readily saturate individual muscles following direct injection, a single injection into muscle 
restrictively transduces the cells localized around the injection site. Skeletal muscle accounts for 
approximately 40% of the whole body in weight. To successfully correct the disorders affecting 
the heart and skeletal muscle, systemic delivery of AAV vectors through the circulation by a 
single intravenous administration is the best way to reach the whole-body transduction of 
muscle. Unfortunately, AAV vectors primarily transduce in the liver and have the broad tropism   
after systemic intravenous delivery. Gene transfer into unwanted nonmuscular tissues decreases 
the efficacy of AAV-mediated transgene expression and raises safety concerns about the 
potential increase of germline transmission. To overcome this challenge in the treatment of 
muscle diseases, the goal of this thesis project is to develop a muscle-specific AAV vector for 
systemic delivery.  
         Compared to other AAV serotypes, AAV2 was the first primate AAV genome to be cloned 
into plasmid in 1980s (255) and has therefore been the best characterized. So AAV2 has been 
chosen as the object in this study. The research of AAV2 tropism modification might build for 
the development of novel tropism on other AAV serotypes. HSPG is the primary receptor of 
AAV2. The residues, R585 and R588 on AAV2 capsid, are primarily involved in heparin 
binding. In contrast, the mutations on R484, R487, or K532 of AAV2 capsid yielded an 
intermediate heparin-binding (250). A study showed the mutations of R484 and R585 from basic 
amino acids to acidic glutamate residues markedly detargeted AAV2 vectors from the liver, and 
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this AAV2 mutant is predominantly retargeted to the heart through systemic delivery in mice 
(256). It appears the possibility that the muscular transduction can be increased by AAV2 with 
mutations on HSPG binding sites due to the reduced vector retention by the liver. Recently, 
White et al. (257) also determined the insertion of endothelial cell-targeting peptide, 
MTPFPTSNEANL, into AAV2 capsid following amino acid 587 could increase its efficiency 
and selectivity for vascular targeting. However, peptide-engineered AAV for muscle targeting 
has not been developed.  
         Based on these findings, the hypothesis in this study is that either the mutations on HSPG 
binding sites of AAV2 capsid or an insertion of the muscle-specific peptide ASSLNIA, isolated 
by phage display (258), on AAV2 capsid could enhance the ability of AAV2 on specific muscle 
targeting and avoid non-specific vector uptake by undesirable tissues.  
The specific aims of this study are: 
1. To characterize and evaluate the muscle-targeting effects, selectivities, and 
neutralizing antibody-evasions of modified AAV2 vectors in vitro 
2. To address the primary pathway of modified AAV2 vectors during viral cell entry 
3. To demonstrate the muscle-targeting abilities of modified AAV2 vectors by local                 
and systemic deliveries after a single administered dose in vivo    
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2. MODIFICATIONS OF AAV2 CAPSID MEDIATE SELECTIVE VECTOR 
TARGETING TO MYOTUBES AND CONFER VIRAL RESISTANCE TO 
NEUTRALIZATION 
2.1 Introduction 
Normal muscle activity is essential for maintaining individual ambulation, respiratory, and 
cardiac function. Undoubtedly, diseases of the striated muscle significantly impair human 
mortality and life quality. A large variety of genetic defects impede the ability of muscle to 
accomplish these tasks and often result in loss of ambulatory capability or heart failure. 
Pharmacological treatment, cell-mediated approach, and gene therapy have been used to 
minimize the damage from myopathy in patients. Among these strategies, gene transfer to 
muscle offers the greatest hope for the treatment of disorders specific to muscle, such as MD. 
AAVs are believed to lack pathogenicity and have shown stable gene expression over a long 
period. These advantages make AAV vector a promising candidate for treatment of MD among 
vector systems applying in human gene therapy. Direct intramuscular injection of AAV vectors 
evokes a high efficiency of gene transfer in the area of injected muscle. However, perfect therapy 
for MD will require whole-body gene transfer to the muscle to insure the patient’s survival. 
Since all serotypes of AAV vector predominantly transduce the liver when given by intravenous 
delivery, the development of an efficient and muscle-specific AAV vector for systemic gene 
transfer needs to be pursued in order to achieve efficacious therapeutic effects without safety 
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concerns. In order to avoid nonmuscular targeting of AAV vectors, genetic modification of AAV 
tropism was conducted. AAV2 was chosen as the target for engineering the specific muscle 
tropism in this study because it is the best characterized among eleven AAV serotypes. AAV2 
infection is initiated by the binding of the virus to cellular HSPG (177). The expression of HSPG 
is widely shown in various tissues. Clearly, this is the reason that AAV2 has broad tropism. 
Although a previous study could not elucidate effects of mutated heparin-binding vectors on 
skeletal muscle targeting due to undetectable reporter activity in muscle tissue, it has 
demonstrated that mutations in heparin-binding sites of the AAV2 capsid redirect vectors to the 
heart from the liver through systemic delivery (256). Based on this finding, modified AAV2 
carrying R484, R585 and R588 mutations in the HSPG-binding motif of the capsid was 
generated and their specificities of skeletal muscle targeting was observed. Retargeting AAV 
vectors by the insertion of specific targeting ligands into the capsid is a feasible approach to 
modify AAV tropism. Samoylova et al. identified a muscle-specific binding ligand by screening 
a phage display library (258, 259). Phages were initially selected after three in vitro rounds on 
C2C12 mouse myotubes. Then, the phages obtained in vitro were injected to mice via tail vein 
injection and were rescued from skeletal muscle. After two rounds of in vivo selections, the clone 
carrying ASSLNIA peptide was isolated and purified as an individual clone. By intravenous 
delivery, the binding of the ASSLNIA phage to mouse skeletal muscle was increased about 
fivefold relative to phage with no insert. The ASSLNIA phages also showed a twofold increase 
in their binding to the heart compared to the control phage. The phage carrying this muscle-
specific peptide also decreased its targeting in the liver, kidney, and brain. Therefore, the muscle-
specific peptide ASSLNIA was genetically incorporated into AAV2 capsid after residue 587 or 
588. The abilities of specific muscle targeting of peptide-inserted vectors were examined in 
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various cell lines. Meanwhile, the present study explored the issue concerning the practicality of 
rAAV2 usage. Although a number of AAV serotypes have been isolated from human and 
nonhuman primate tissues, rAAV2 is the only serotype that has been used in clinical trials for the 
treatment of hemophilia, cystic fibrosis, DMD, and other diseases. Despite the well-established 
safety of rAAV2 vectors for gene delivery in humans, the major obstacle to the efficacy of 
AAV2 vectors in vivo is the prevalence of preexisting neutralizing antibodies in individuals 
previously exposed to AAV2. Hence, the modified AAV vectors were tested for the evasion of 
neutralizing antibodies in vitro. These in vitro examinations have clearly demonstrated muscle-
targeting efficiency, selectivity, and immune escape of modified AAV2 vectors.  
2.2 Material and methods 
2.2.1 Cell culture  
C2C12 murine myoblasts (American Type Culture Collection, Rockville, Maryland), human 
hepatocellular carcinoma HepG2 cells, human cervical carcinoma HeLa cells, human embryonic 
kidney 293 cells (HEK 293 cells), and human glioblastoma tumor U-87MG cells were grown in 
Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS). To 
induce the differentiation of C2C12 myoblasts, 1x104 C2C12 myoblasts per well in 24-well 
plates were first grown for up to 3 days in DMEM supplemented with 10% FBS and then, they 
were differentiated from C2C12 myoblasts to C2C12 myotubes in the presence of DMEM and 
2% horse serum (HS). After 4 days of differentiation, the C2C12 myotubes were formed.    
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2.2.2 Plasmid construction 
The plasmid pBSKS-AAV2Cap containing AAV2 cap gene was used as the template for the 
construction of all modified capsids. Mutagenesis was achieved by using PCR. The mutations of 
heparin binding sites on AAV2 capsid were introduced by the mutagenic primers which contain 
the desired mutation. For the peptide-modified capsid, we designed the primers encoding amino 
acids ASSLNIA flanked by peptide linker. This muscle-specific peptide (ASSLNIA) was then 
inserted into the site after residue 587 of AAV2 capsid by PCR. The synthesized PCR products 
were digested with DpnI endonuclease to eliminate the parental plasmid template and further 
added phosphates at 5’of oligonucleotides by T4 polynucleotide kinase (New England BioLabs) 
to allow subsequent ligation. The modified AAV2 containing the mutations on heparin binding 
sites with the peptide insertion after amino acid 587 of capsid was also generated. The sequences 
of primers are listed in Table 1. The modified Cap gene was then subcloned from pBSKS-
AAV2Cap to pXX2 (260) by EcoRV and Xcm I. 
Table 1 The primers for constructing the modified AAV2 capsids 
Primer                               Sequences
--------------------------------------------------------------------------------------------------------------------
1) Primers for the mutagenesis of heparin binding sites:
R484E+                             5’AGC AGC AGC GAG TAT CAA AG 3’
R484E– 5’CGT AAC AGG GTC AGG AAG C 3’
R585A– 5’TGC CTG GAG GTT GGT AGA TAC AGA ACC AT 3’
R588A+                             5’GGC AAC GCA CAA GCA GCT ACC GCA GAT GTC 3’
2)  Primers for the ASSLNIA peptide insertion:
587 TG MTP+                   5’AAC ATC GCC GGA TTA AGT AGA CAA GCA GCT
ACC GCA 3’
587 TG MTP– 5’GAG GGA GGA AGC TCC TGT GTT GCC TCT CTG 
GAG GTT 3’
--------------------------------------------------------------------------------------------------------------------
588 HB MTP+                   5’AAC ATC GCC GCC GCC CAA GCA GCT ACC GCA    
GAT 3' 
588 HB MTP– 5’GAG GGA GGA GGC GCG GCG GTT GCC TCT CTG 
GAG GTT 3’
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2.2.3 Molecular modeling 
The location of the inserted muscle-specific ligand on the VP3 domain of the AAV2 capsid was 
generated by Swiss-Model (261-264). Swiss-Model is an automated comparative protein 
structure modeling server provided by the Biozentrum (University Basel) and the Advanced 
Biomedical Computing Center (NCI Frederick, USA). The ribbon drawing of either the peptide-
modified or wild-type AAV2 VP3 subunits was produced with the available coordinates of 
AAV2 (201) (Protein Databank accession no. 1LP3) supplied as a template. DeepView/Swiss-
Pdb Viewer revealed the surface charge distribution on the VP3 subunit with or without the MTP 
insertion. 
2.2.4 rAAV vector production         
To produce modified rAAV2 virus, the three-plasmid cotransfection method was applied in HEK 
293 cells (205). The plasmids used in transfection were the following: i) ssAAV CMV-Luc 
plasmid with the luciferase (Luc) gene driven by the CMV promoter, or dsAAV CB-EGFP 
plasmid with the enhanced green fluorescent protein (EGFP) gene controlled by the CB promoter 
(CMV enhancer/chicken beta-actin promoter). Both plasmids carry the promoter-driven 
transgene flanked by AAV ITRs (Figure 1); ii) the pXX6 plasmid, which contains the helper 
genes from adenovirus; iii) the modified pXX2 plasmid, which supplies AAV2 rep protein and 
modified capsid protein. As a control, wild-type rAAV was also prepared with unmodified pXX2 
plasmid expressing wild-type AAV2 capsid protein. These three plasmids were mixed at a 2:3:1 
molar ratio. Transfections were carried out by the following procedures. HEK 293 cells were 
split and reached 80% confluency for transfection. Twenty 15-cm plates were transfected by 
using the calcium phosphate system. After 48 hours of transfection, cells were trypsinized and 
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harvested by centrifugation at 3,000 rpm for 10 minutes. Cell pellets were resuspended in 
DMEM, and the virus was released by freezing and thawing three times. The crude lysate was 
then treated with benzonase (Sigma), at 50 units/ml final concentration, at 37˚C for two hours. 
The virus was further purified twice through CsCl density gradient ultracentrifugation. 
         rAAV genomic titers were determined by DNA dot-blot assay. Briefly, 2 µl of the purified 
rAAV stock was digested with DNase I (10 µg/ml) in DMEM at 37˚C for one hour and then 200 
µl of 2x proteinase K buffer (20 mM Tris.Cl pH 8.0, 20 mM EDTA pH 8.0, 1% SDS) was added. 
Next, proteinase K was added to reactions at a final concentration of 1 mg/ml and the samples 
were incubated at 55˚C for one hour. Viral DNA was precipitated by ethanol and the DNA pellet 
was dissolved in an alkaline buffer (0.4 M NaOH, 10 mM EDTA pH 8.0). DNA samples were 
applied to Nylon membranes and probed with a horseradish-peroxidase-labeled CMV or EGFP 
probe. Signals were detected by the North2South® chemiluminescence kit (Pierce). In order to 
detect if these mutant virions were composed of three capsid proteins, 2x1010 viral particles of 
unmodified or modified ss rAAV CMV-Luc virus were subjected to Western blot with anti-
AAV2 capsid guinea pig sera provided by R. J. Samulski (University of North Carolina).  
 
ITR        D CMV                    Luciferase A D        ITR
trs trs
ITR                CB                    EGFP                                 A D        ITR
trs
      iferase IT
I                 CB                    EGFP                                        IT
ssAAV CMV-Luc
dsAAV CB-EGFP  
 
Figure 1 rAAV genomic plasmids for vector production    
 
The conventional ssAAV CMV-Luc plasmid (Upper) has two ITRs flanking the luciferase gene expression 
cassette controlled by the CMV promoter. This plasmid can produce ss rAAV virus harboring the luciferase 
reporter gene. For dsAAV CB-EGFP plasmid (Lower), there is a deletion of the D sequence together with the 
adjacent trs from one of AAV ITRs and is able to generate ds rAAV virus carrying EGFP reporter gene 
driven by the CB promoter (213).  
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2.2.5 In vitro transduction assay 
C2C12 myotubes were grown in 24-well plates and infected with rAAV CMV-Luc vectors at 
2x1010 genomic particles/per well. After three days of transduction, myotubes were given fresh 
DMEM containing 2% horse serum (HS) and subsequently incubated at 37˚C for 6 days. Then, 
myotubes were lysed for the luciferase assay. For ds rAAV CB-EGFP virus, C2C12 myotubes 
were treated with ds rAAV CB-EGFP vectors at 1x1010 genomic particles/per well. EGFP 
expression was observed under a Nikon TE-300 inverted fluorescent microscope. Images were 
taken at 100x magnification at 72 hours after infection.  
         C2C12 myoblasts (2x104 cells/well) were grown in 12-well plates overnight. These cells 
were infected with rAAV CMV-Luc at 104 genomic particles/cell and adenovirus type 5 (Ad5) at 
an MOI of 5 plaque forming units/cell for 48 hours. Reporter gene activities were further 
determined by the luciferase assay. 
         1x105 HepG2 cells per well were seeded in 12-well plates and these cells were incubated 
with rAAV CMV-Luc vectors at 103 genomic particles/cell in the presence of Ad5 at an MOI of 
10 plaque forming units/cell for 48 hours. Cells were then harvested for the luciferase assay. 
         HeLa cells (6x104 cells/well) or 3x105 HEK 293 cells per well were grown in 12-well 
plates for 24 hours. These cells were then infected with rAAV CMV-Luc at 103 genomic 
particles/ per cell and Ad5 at an MOI of 5 plaque forming units/cell for 48 hours. To test 
transduction efficiencies, luciferase activities were determined by the luciferase assay. 
         U-87MG cells were grown at a density of 3x104 cells/well in 12-well plates overnight and 
then infected with rAAV at 104 genomic particles/cell for 48 hours. Reporter gene activities were 
determined by the luciferase assay.   
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         rAAV-mediated in vitro transduction experiments were repeated independently at least two 
or three times in triplicate.  
2.2.6 In vitro neutralization assay 
This assay was developed to determine the effect of a preexisting anti-AAV immune response on 
modified rAAV2 vectors in vitro. 2x1010 particles of ss rAAV CMV-Luc vector or 1x1010 
particles of ds rAAV CB-EGFP virus were preincubated with anti-AAV2 capsid guinea pig 
polyclonal serum diluted in phosphate-buffered saline (PBS) for 45 minutes at room temperature 
in a total volume of 50 µl. The final dilution of anti-AAV2 capsid guinea pig sera was from 
1:500 to 1:2000. These virus-serum mixtures were added to C2C12 myotubes in a final volume 
of 450 µl and incubated for 72 hours. For ss rAAV CMV-Luc infection, C2C12 myotubes were 
then changed to fresh DMEM containing 2% HS. After subsequent incubation at 37˚C for 6 
days, cells were collected for the luciferase assay. Myotubes transduced with the ds rAAV CB-
EGFP virus were examined for EGFP expression by fluorescent microscope after incubation 
with the virus-serum mixture for 72 hours. 
         The neutralization assay also explored the issue concerning the practicality of modified 
rAAV2 usage in human clinical application. Pooled, purified, human intravenous 
immunoglobulin G (IVIG) was purchased from Sigma and solubilized by PBS to a concentration 
of 100 mg/ml. IVIG dilutions ranging from 1:50 to 1:500 were then made in PBS. 2x1010 ss 
rAAV CMV-Luc vectors were then exposed to various human IVIG dilutions at 37˚C for 60 
minutes. Subsequently, the ss rAAV CMV-Luc-serum mixtures were added in C2C12 myotubes 
for 72 hours at 37˚C. Next, viruses were removed by replacing with fresh DMEM with 2% HS. 
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Cells were incubated for 6 days and were then harvested for the luciferase assay. The 
neutralizing effect of human IVIG was analyzed by examining inhibition of luciferase activity.  
         The neutralizing titer was determined as the dilution of antibody at which 50% of 
transduction was inhibited. Neutralizing experiments were performed in triplicate in two 
independent experiments. 
2.2.7 Luciferase assay 
The harvested cell pellets were washed with 1x PBS and then lysed in 100 µl of luciferase lysis 
buffer (0.05% Triton X-100, 0.1 M Tris-HCl pH 7.8, 2 mM EDTA). The lysate was subsequently 
treated by freezing and thawing three times. The lysate was centrifuged at 12,000 rpm for 15 
minutes in 4˚C and 20 µl or 40 µl of supernatant was measured for light activity using the 
luciferase kit (Promega) with a luminometer. Protein content in each sample was determined by 
Bradford protein assay (BioRad). Luciferase activities were expressed as relative light units per 
milligram of protein (RLU/mg protein).         
2.2.8 Statistical analysis 
         Unpaired Student’s t test was performed by one- or two-tailed test. All in vitro data were 
tested and were considered significant when P < 0.05. Data were shown as mean±SEM.  
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2.3 Results 
2.3.1 Generation of AAV2 capsid mutants  
A previous study used alanine substitution mutagenesis to discover that the mutation of arginine 
residues at positions 585 or 588 completely eliminates the heparin-binding ability of AAV2 
(250). In addition, the substitution of the arginine residues at positions 484 and 585 with acidic 
glutamate residues resulted in significantly reduced infection of liver tissue without affecting 
transduction of the heart using intravenous delivery (265). For these reasons, the mutant AAV2 
capsid carrying triple mutations on the heparin-binding sites of AAV2 capsid was generated. 
This heparin-binding mutant (HBSmut) has the mutations at positions 585 and 588 from arginine 
to alanine, and the substitution of the arginine at amino acid 484 with glutamate (Figure 2).  
         Using the insertion of a peptide containing RGD motif, a group identified that positions 
after residues 139, 584, and 587 are tolerant to peptide insertion with display of the ligand on the 
particle surface (266, 267). According to this, the insertion of heterologous peptide after residue 
587 of AAV 2 capsid has received the most attention since it locates between residues R585 and 
R588, the primary heparin-binding motif of AAV2 capsid. Hence, it has the potential to 
simultaneously disrupt heparin binding of AAV2 and retarget AAV2 vectors to a desirable 
tissue.  
         The peptide ASSLNIA was selected for the targeting of murine myofibers in vivo (258). In 
the present study, this muscle-specific peptide was introduced after amino acid 587 of the capsid 
gene (Figure 2). Since a recent work showed that different linker sequences flanking the inserted 
peptide correspond to the targeting effect of the peptide (266), two MTP-inserted mutants with 
different peptide linkers (587 TG MTP and 588 HB MTP) were designed. 587 TG MTP virus 
does not retain the heparin binding motif of the capsid at the site of peptide insertion while the 
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insertion of exogenous peptide on 588 HB MTP capsid still remain residues primarily involved 
in heparin binding. The modified AAV2 vector combining the mutations on heparin binding sites 
with the peptide insertion after amino acid 587 of capsid (HBSmutMTP) was also constructed. 
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Figure 2 Schematic representation of modified AAV2 capsid amino acid sequences 
Constructs were generated with residue mutations, MTP insertions flanked by two different linkers, or the 
combination of residue mutations and MTP insertion. Changes compared to the wild-type AAV2 amino acid 
sequence are highlighted in red letters. There are five putative loop regions (Loop I-V) within AAV2 capsid 
protein. Insertions of muscle-specific peptide are displayed at Loop IV, which is in a pocket conformation as a 
receptor anchor (268).  
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         Sixty monomers of the VP1, VP2, and VP3 structural proteins assemble to form an intact 
AAV2 viral particle. Since the capsid proteins, VP1, VP2, and VP3 share overlapping sequences 
at their C termini including a peptide-insertion site after position 587, the small targeting peptide 
introduced after residue 587 is present in all 60 capsid subunits that make up the viral particle 
(Figure 3). Therefore, sixty muscle-specific peptides are present on a modified virion. 
 
p5               p19      p40
Rep                                                             Cap                            A
Terminal 
repeat
Terminal 
repeat
ASSLNIA
N587
VP1
VP2
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Figure 3 Topology of the AAV2 capsid with inserted muscle-specific peptide 
Introducing the coding sequence of MTP that directs specific muscle binding on AAV2 cap gene mediates the 
production of muscle-targeting rAAV virus. The inserted MTP (red) is displayed at the fivefold axis of 
symmetry of each subunit on the surface of AAV2 virion (green) (269).   
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         The X-ray structure of AAV2 capsid was used to analyze the peptide-inserted capsid 
structures at the molecular level. Compared to the structure of wild-type AAV2 VP3 monomer 
(Figure 4), an external loop, containing the RXXR domain (X is any amino acid), that conferred 
a heparin-binding phenotype was missing in the 587 TG MTP VP3 subunit (Figure 5). In 
contrast, 588 HB MTP retained the loop structure containing the RXXR motif similar to that of 
wild-type AAV2 capsid subunit (Figure 6). The insertion of MTP ligand did not destroy this loop 
structure which was required for heparin binding in 588 HB MTP virus. The surface charge 
distribution on the VP3 subunits from peptide-modified mutants was also examined. As expected, 
both unmodified and 588 HB MTP VP3 monomers had shown a positive charge on the loop-like 
structure presenting the RXXR motif (Figure 7). Although 587 TG MTP VP3 had the positively 
charged force at the C-terminal of the inserted peptide, this location did not have an extended 
loop-like structure available for heparin binding and the heparan sulfate consensus-binding 
sequences required at least two basic residues close to each other which were also missing at this 
positively charged area (270). 
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Figure 4 Ribbon drawing of the wild-type AAV2 VP3 subunit 
Small arrow indicates the location of residue 587. The molecular model was generated by Swiss-Model.  
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Figure 5 Ribbon representation of a 587 TG MTP VP3 monomer 
The inserted muscle-specific ligand is highlighted in red. The amino acids displayed on the unmodified 
rAAV2 are represented as green. This capsid monomer was generated using Swiss-Model. 
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Figure 6 Ribbon representation of a 588 HB MTP VP3 monomer 
The inserted muscle-specific ligand is highlighted in red. The amino acids displayed on the unmodified 
rAAV2 are represented as green. Small arrow indicates the location of R588. The loop containing the 
heparin-binding motif, the RXXR domain, is marked by blue rectangle. This capsid monomer was generated 
using Swiss-Model. 
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Figure 7 The electrostatic surface potential of VP3 monomers 
The electrostatic surface potential of VP3 subunits were calculated with Coulomb. Red dots indicate the 
negatively charged regions and blue dots reveal the positively charged areas.  
 
 
 
 
 63 
         DNA dot-blot assays were performed to detect the viral yields of all mutant AAV vectors. 
The dot-blot assay examines the titer of AAV particles that contain DNase-resistant AAV 
genomes. The HBSmut, 587 TG MTP, and 588 HB MTP mutants created modified AAV2 
vectors with titers comparable to that of wild-type AAV2. However, the HBSmutMTP mutant 
was tested negative by the dot-blot assay. This result implied that a combination of peptide 
insertion and heparin-binding mutations led to unwanted damage in viral assembly or packaging 
due to the creation of too many modifications within the cap gene. Either the mutant capsids of 
HBSmutMTP were unstable and no longer protected vector genomes from DNase digestion, this 
mutant generated empty viral particles, or the mutant produced intact AAVs at a low yield and 
the sensitivity of the dot-blot assay was not sufficient to detect low numbers of packaged viral 
genomes. 
         To confirm the capsid protein composition of modified rAAVs, Western blotting was 
utilized to determine viral proteins from virus preparations having equivalent numbers of 
genome-containing virions (Figure 8). The stoichiometry of the VP1, VP2, and VP3 proteins 
from the heparin-binding mutant (HBSmut) or peptide-modified viruses (587 TG MTP and 588 
HB MTP) was similar to that of the three capsid proteins from the wild-type virion.           
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Figure 8 Capsid protein analysis of modified rAAV2 vectors by Western blot 
Similar numbers of rAAV genome-containing particles (2x1010) were separated on 10% SDS-PAGE and 
analyzed by Western blot, using anti-AAV2 capsid guinea pig sera.  
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2.3.2 Transduction efficiencies of modified vectors in cultured myotubes 
Previous studies have shown that rAAV2 vectors can transduce muscle cells to result in the 
expression of therapeutic genes via intramuscular injection (271, 272). However, the relative 
infectivity of AAV2 for muscle fibers compared with other cell types, such as immortalized cell 
lines, or hepatocytes is low (265). The reason for this inefficiency of muscle transduction may 
reflect insufficient interaction between AAV capsid and the cell surface receptor of muscle. In 
order to validate the muscle-transduction efficiencies of these capsid mutants in vitro, murine 
C2C12 myotubes were used here because MTP incorporated into the AAV capsid was originally 
isolated from phage selection in C2C12 myotubes (258) and differentiated C2C12 myotubes 
express many of the proteins presented in adult skeletal muscle. Using ss rAAV vectors 
expressing the luciferase reporter gene from the CMV promoter, these modified vectors were 
initially tested for their abilities to infect C2C12 myotubes (Figure 9). Compared to unmodified 
vector, the peptide-modified ss rAAV 587 TG MTP and ss rAAV 588 HB MTP viruses with a 
genomic particle amount of 2x1010 were able to transduce differentiated C2C12 myotubes 
(P>0.05). In comparison to unmodified ss rAAV transduction efficiency, peptide-modified ss 
rAAV 588 HB MTP vector containing heparin binding motif showed a 47.47% increase in 
myotube transduction although ss rAAV 587 TG MTP vector transduction decreased 
approximately 26.28%. In marked contrast, impairment of the heparin-binding sites of capsid by 
mutation significantly reduced viral transduction in C2C12 myoutubes. ss rAAV HBSmut was 
unable to achieve more than 0.038% transduction efficiency as compared to unmodified ss rAAV 
virions (P<0.05).  
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Figure 9 Efficiency of modified rAAV-mediated gene transfer to C2C12 myotubes 
Mouse C2C12 myotubes were infected with 2x1010 genomic particles/well of ss rAAV CMV-Luc vector which 
carries either unmodified capsid, peptide-inserted capsid, or heparin-binding mutated capsid in 24-well 
plates. After 3 days, myotubes were replaced by fresh DMEM containing 2% HS and subsequently incubated 
for 6 days. Luciferase activity was then analyzed to evaluate the transduction efficiencies of modified rAAV 
vectors. Compared to unmodified vector, peptide-modified vectors, 587 TG MTP and 588 HB MTP, 
maintained their transduction efficiencies in C2C12 myotubes (P>0.05) while the heparin-binding mutant 
(HBSmut) remarkably decreased its myoutube infectivity (P<0.05). *P<0.05 vs unmodified rAAV2 vector.      
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         To confirm that these muscle-targeting effects of modified rAAV vectors were exclusively 
due to the modification of viral capsid, an additional control experiment was performed, where 
the transduction assay in C2C12 myotubes was carried out with ds rAAV vectors expressing the 
EGFP indicator gene from the CB promoter (Figure 10). As expected, this experiment yielded 
similar results when myotubes were infected with 1x1010 of unmodified or modified ds rAAV 
CB-EGFP vectors. Based on the determination of EGFP expression, ds rAAV 587 TG MTP 
vector showed less effective myotube transduction than unmodified ds rAAV vector. In addition, 
the EGFP signal detected in ds rAAV 588 HB MTP-infected myotubes was comparable to that 
of myotubes infected by unmodified virus. The heparin-binding mutant dramatically eliminated 
luciferase activity driven by the CMV promoter in ss rAAV HBSmut-transduced C2C12 
myotubes (Figure 9). Similarly, EGFP-positive myotubes were essentially undetectable in the 
infection of ds rAAV HBSmut vectors containing the CB-EGFP expression cassette (Figure 10).  
          Taken together, these results highlighted the simple insertion of MTP coding sequence in 
capsid is a more feasible way to manage AAV muscle tropism than the heparin-binding mutation 
of viral capsid. In addition, the transduction efficiencies of modified rAAV vectors in C2C12 
myotubes are solely directed by their capsid modifications, since vectors with different 
expression cassettes yield the same results. 
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Figure 10 Examination of rAAV vectors in myotube transduction by fluorescent microscopy 
 
C2C12 myotubes were transduced with ds rAAV CB-EGFP vectors at 1x1010 genomic particles/per well in 
24-well plates. EGFP expression driven by the CB promoter was then observed under a Nikon TE-300 
inverted fluorescent microscope. Pictures were taken at 72 hours after infection. Fluorescent photography is 
shown in the upper panel and the morphology of C2C12 myotubes on the same field as the fluorescent image 
is displayed in the lower panel. Peptide-modified vectors, 587 TG MTP and 588 HB MTP, revealed their 
infectivities in myotubes, but the heparin-binding mutant completely lost its ability to transduce cultured 
myotubes. Scale bar, 100µm. 
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2.3.3 Targeting selectivities of modified vectors 
In addition to targeting ability to the desired cell type, safety and efficacy of retargeted AAV 
vectors would be further enhanced by avoiding vector uptake into non-target cells. The ultimate 
aim in this study is to generate a muscle-specific AAV vector for mature myotube targeting in 
order to cure diseased myofibers. Thus, rAAV-mediated gene transfer in myoblasts is not 
desired.  
         To evaluate the selectivity of modified vectors, undifferentiated murine C2C12 myoblasts 
(the progenitor cell line of differentiated C2C12 myotubes) were infected with modified rAAV 
CMV-Luc vectors carrying either wild-type capsid or modified capsid. In direct contrast to 
reporter gene expression produced in C2C12 myotubes, peptide-modified vectors, rAAV 587 TG 
MTP and rAAV 588 TG MTP, remarkably lowered reporter gene expression than unmodified 
rAAV in C2C12 myoblasts (P<0.05) (Figure 11). rAAV 587 TG MTP vector resulted in a 
92.59% decrease in gene expression in myoblasts and rAAV 588 HB MTP vector reduced its 
myoblast transduction by 96.95%. Similarly, rAAV HBSmut displayed extremely low infectivity 
in C2C12 myoblasts compared to the unmodified virus (P<0.05). 
         According to these observations, there was the possibility that the cellular receptor 
recognized by the muscle-targeting peptide is downregulated in the undifferentiated C2C12 
myoblasts (273).  
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Figure 11 Effect of capsid modification on rAAV-mediated gene transfer in C2C12 myoblasts 
C2C12 myoblasts were infected with rAAV vectors in the presence of Ad5 and luciferase activity was 
analyzed 48 hour later. Ad5 coinfection was utilized to maximize rAAV transduction by enhancement of 
vector second-strand synthesis (274). *P<0.05 vs unmodified rAAV2 vector. 
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         rAAV vectors have a predominantly hepatic tropism when delivered systemically (275, 
276). In neonates, vector genomes transduced in the liver are rapidly degraded when hepatocytes 
undergo cell division during liver growth. However, AAV vector DNA sequestered in the adult 
liver remains stable because the liver cells are largely quiescent in adults (148). Therefore, 
undesired liver targeting not only hampers transduction efficiency at the muscle, but also gives 
rise to safety concerns about accumulation of large amounts of vector DNA in the adult liver, 
where targeted viral DNA is difficult to be cleaned out by host spontaneous mechanism.  
         In this regard, ss rAAV CMV-Luc carrying different peptide-modified capsids was used to 
examine if peptide-modified rAAV vectors retained with them a native tropism of AAV2 toward 
the infection of HepG2 cells, a human hepatocellular carcinoma cell line. Compared to 
unmodified AAV2 virus, CMV-driven luciferase expression from rAAV 587 TG MTP totally 
abolished in transduction of HepG2 cells (P<0.05) (Figure 12). Furthermore, rAAV 588 HB 
MTP represented a 10.72-fold decrease in luciferase activity of infected HepG2 cells (P<0.05).  
         These results show that the insertion of the muscle-targeting peptide after residue 587 of 
capsid dramatically detargeted peptide-modified vectors from hepatocytes while these peptide-
modified vectors maintained their ability to transduce myotubes at an acceptable level. 
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Figure 12 Peptide-modified rAAV vectors in gene delivery to a human liver-derived cell line 
HepG2 cells were transduced by rAAV at 103 genomic particles/cell in the presence of Ad5. Cells were then 
lysed and luciferase activity was determined at 48 hours after infection. *P<0.05 vs unmodified rAAV2 
vector. 
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         Using ss rAAV vectors containing the luciferase gene under control of the CMV promoter, 
this study next sought to determine whether modified rAAV vectors displayed selectivity in a 
number of human non-muscle cell lines. For this purpose HeLa cells, the human cervix 
epithelioid carcinoma cell line, was first employed in testing targeting specificity of modified 
AAV2 vectors. As demonstrated by luciferase enzyme activity, transduction of HeLa cells with 
rAAV HBSmut, rAAV 587 TG MTP, or rAAV 588 HB MTP vectors resulted in a 97.96%-
99.51% decrease in reporter gene activities compared to the vector carrying a wild-type capsid 
(P<0.05) (Figure 13).  
         Moreover, HEK 293 cells, a human embryonic kidney cell line, were also infected with 
modified AAV2 vectors to ensure the specific targeting effect from these mutant vectors. 
Consistently, rAAV HBSmut, rAAV 587 TG MTP, and rAAV 588 HB MTP viruses were 
significantly impaired in their ability to transduce of HEK 293 cells with efficiencies ranging 
from 0.45% to 2.69% of unmodified AAV2 transduction (P<0.05) (Figure 14).  
         Finally, this study further assessed if peptide-modified vectors could alter their targeting 
effects in the human glioblastoma tumor U-87MG cells to decrease nonspecific targeting. The 
result showed that transduction efficiencies of rAAV 587 TG MTP and rAAV 588 HB MTP 
vectors in U-87MG cells were very poor compared to unmodified vectors (P<0.05) (Figure 15). 
         These in vitro transduction assays demonstrated that rAAV HBSmut vector fails to mediate 
gene expression in all tested cells including C2C12 myotubes. In contrast, both peptide-modified 
vectors are capable of targeted gene delivery to myotubes and efficiently eliminate their targeting 
in non-target cells. It is possible that the targeted receptor of the selected muscle-targeting 
peptide is not ubiquitously expressed or activated on non-muscle cells. 
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Figure 13 Infection of rAAV vectors in human cervix epithelioid carcinoma HeLa cells 
HeLa cells were exposed for 48 hours to either modified or unmodified ss rAAV CMV-Luc vectors at an MOI 
of 103 with Ad5 coinfection. Cells were then harvested for luciferase assay. *P<0.05 vs unmodified rAAV2 
vector.     
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Figure 14 Gene delivery mediated by rAAV vectors in human embryonic kidney 293 cells 
HEK 293 cell transduction rates were assessed after preincubation of the cells with ss rAAV CMV-Luc vector 
at an MOI of 103 in the presence of Ad5 for 48 hours. *P<0.05 vs unmodified rAAV2 vector. 
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Figure 15 Luciferase expression in human glioblastoma tumor U-87MG cells with rAAV transductions 
ss rAAV CMV-Luc vectors at an MOI of 104 were incubated with U-87MG cells for 48 hours at 37˚C. Cells 
infected with either modified or unmodified rAAV vectors were then lysed and analyzed for luciferase 
activity. *P<0.05 vs unmodified rAAV2 vector. 
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2.3.4 Neutralization profiles of peptide-modified rAAV vectors 
Humoral immunity is the predominant host immune response following either wild-type AAV 
infection or rAAV transduction (277-279). The presence of serum antibodies directed against 
AAV2 is very common in humans. For practical application of human gene therapy, this is 
potentially important because the preexisting immunity against vector capsid could impede in 
vivo rAAV transduction. Therefore, immune responses to AAV-based vectors need to be 
resolved when bringing this vector system to the clinic. Engineering of rAAV vector capsids to 
circumvent host antivector immune responses is an attractive approach to overcome preexisting 
AAV immunity and to facilitate vector readministration. A previous study has demonstrated that 
a 14 amino-acid peptide insertion after residue 587 of AAV2 capsid enables the vector to escape 
the effects of the neutralizing antibody (222). According to this, the resistance of MTP-inserted 
rAAV vectors to antibody-mediated neutralization was determined in here. 
         First, the interference of anti-AAV2 capsid guinea pig serum with unmodified or peptide-
modified ss rAAV CMV-Luc transduction in C2C12 myotubes was analyzed since guinea pig 
serum used in this study has been performed as a positive control to characterize the presence 
and specificity of anti-AAV antibodies in humans (221). Neutralizing titers were defined as the 
antibody dilution where viral transduction was reduced by 50% (N50). The applied serum and 
antibody reagent acted as neutralizers when the N50 for unmodified AAV2 was 1:320 or higher, 
in agreement with previously published studies (222). At a 1:2,000 serum dilution, unmodified 
AAV2 vector was completely neutralized while peptide-inserted mutants, 587 TG MTP and 588 
HB MTP, still retained substantial infectivity (Table 2 and Figure 16). The N50 of unmodified 
virus was determined as 1:6,315. ss rAAV 587 TG MTP produced the neutralizing titer at a 
dilution of 1:1,450 and ss rAAV 588 HB MTP did not reduce transduction to 50% even at a 
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1:500 serum dilution. Interestingly, over 10% of ss rAAV 587 TG MTP virions remained 
infectious and 62.75% of ss rAAV 588 HB MTP vectors possessed transduction ability when the 
neutralization assay was performed at the lowest serum dilution of 1:500 that totally inhibited 
luciferase activity from unmodified vector infection. At this dilution, 587 TG MTP and 588 HB 
MTP vectors demonstrated 77- and 481-fold enhanced resistance, respectively, to neutralizing 
antibodies compared to the unmodified vector (P<0.05).  
         ds rAAV CB-EGFP vectors were also used to assess the resistance of peptide-modified 
vectors to neutralization by guinea pig antiserum. As described above, C2C12 myotubes infected 
with unmodified ds rAAV CB-EGFP virus completely lost EGFP expression in the presence of 
guinea pig anti-AAV2 serum at a 1:1,000 dilution (Figure 17). Transduction by ds rAAV 587 TG 
MTP vector yielded detectable EGFP-positive myotubes at a 1:500 dilution. In addition, ds 
rAAV 588 HB MTP vector was able to escape the neutralizing antibodies in guinea pig serum 
and enabled myotubes to display the strong EGFP signal at a serum dilution of 1:500. 
         Although both peptide-incorporated vectors showed resistance to guinea pig antiserum 
neutralization, 588 HB MTP vector was superior to 587 TG MTP vector in escaping the 
preexisting humoral immune responses. 
Table 2 Neutralization of peptide-modified AAV vectors by guinea pig antiserum 
rAAV vector                                     Neutralizing titer (N50)
Unmodified rAAV2                                          1:6,315
rAAV 587 TG MTP                                          1:1,450
rAAV 588 HB MTP                                          < 1:500
                                          
 
The N50 was calaulated by using the Reed-Muench formula (280). Data represents as 
                                             the dilution of serum that completely inhibited viral transduction in 50% of the cells.  
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Figure 16 Effect of guinea pig anti-AAV2 serum on peptide-modified rAAV infection of C2C12 myotubes 
Differentiated myotubes were infected with ss rAAV CMV-Luc vector alone or after coincubation with anti-
AAV2 cap guinea pig serum at an indicated serum dilution. Myotubes were then analyzed for luciferase 
activity at 9 days after infection. Transduction by unmodified rAAV was completely suppressed with a serum 
dilution of 1:2,000 (P<0.05). Even at a serum dilution of 1:1,000 or 1:500 (much lower than the N50 of 
unmodified rAAV), peptide-modified vectors, 587 TG MTP and 588 HB MTP, were significantly more 
resistant to neutralization than unmodified rAAV (P<0.05). 
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Figure 17 Neutralizing activity against peptide-modified rAAVs in guinea pig antiserum 
C2C12 myotubes were infected with ds rAAV CB-EGFP vector alone (left panel) or after coincubation with 
guinea pig antiserum at a dilution of 1:1,000 (middle panel) or 1:500 (right panel). EGFP expression was 
detected by fluorescence microscopy at 72 hours after transduction. Scale bar, 100µm. Infection of 
unmodified rAAV resulted in undetectable EGFP signal at a serum dilution of 1:1,000. Unlike unmodified 
rAAV, 587 TG MTP and 588 HB MTP vectors conferred neutralization resistance to guinea pig antiserum at 
a serum dilution of 1:1,000 and 1:500. 
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         In an attempt to explore whether peptide-inserted vectors were resistant to antibody 
neutralization in a large portion of the human population, human IVIG was utilized in the 
neutralization assay. IVIG is purified human IgG and it is isolated from pooled human serum. 
Because IVIG is prepared from thousands of normal blood donors, it represents nearly all 
immune responses within the donor population. In this study, the donor population of IVIG 
(Sigma) is restricted to individuals in USA. All commercial sources of human IVIG have been 
proven to contain high AAV2 neutralizing titers ranging from 1:1,043 to 1:3,330 at an IgG 
concentration of 100 mg/ml (281).    
         When conducting the in vitro neutralization assay with human IgG, ss rAAV CMV-Luc 
vectors were preincubated with different dilutions of IVIG (100 mg/ml) before transduction of 
C2C12 myotubes. After 9 days of infection, luciferase activity was measured to evaluate the 
neutralizing resistance of peptide-modified mutants. At an IVIG dilution of 1:500, transduction 
by 587 TG MTP vector was severely impaired as that of unmodified AAV2 vector. Unmodified 
rAAV and rAAV 587 TG MTP vectors reduced their transgene expression by 76.34% and 
89.62%, respectively (Table 3 and Figure 18). In contrast, 588 HB MTP vector was 2.31- to 
5.26-fold more resistant to neutralization by IVIG (P<0.05) and delivery of 588 HB MTP vector 
only yielded 45.35% reduction in luciferase activity at the same IVIG dilution. Even at a 1:250 
IVIG dilution, 588 HB MTP vector still had an infectivity up to 53.59% while unmodified rAAV 
and 587 TG MTP vectors showed no more than 14% transduction (P<0.05). Strikingly, 
transduction of 588 HB MTP vector exhibited a 14.68-fold improvement compared to 
unmodified vector (P<0.05) when the neutralization assay was using a 1:50 IVIG dilution that 
completely neutralized unmodified and 587 TG MTP vectors. Moreover, unmodified rAAV and 
587 TG MTP vectors generated the neutralizing titer at an IVIG dilution of 1:1,106 and 1:1,383, 
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respectively. The neutralizing titer of 588 HB MTP virus was determined as a 1:423 IVIG 
dilution. 
         According to these data, only 588 HB MTP vector had a significantly increased level of 
resistance to IVIG neutralization.   
 
Table 3 Neutralization of peptide-inserted mutants by human IVIG 
rAAV vector                                     Neutralizing titer (N50)
Unmodified rAAV2                                          1:1,106
rAAV 587 TG MTP                                          1:1,383
rAAV 588 HB MTP                                          1:423
 
                                         The N50 was calaulated by using the Reed-Muench formula (280). Data represents as  
                                         the dilution of serum that completely inhibited viral transduction in 50% of the cells.  
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Figure 18 Characterization of rAAV neutralizing profile to human IVIG in C2C12 myotubes 
Differentiated myotubes were transduced with ss rAAV CMV-Luc vector alone or after coincubation with 
human IVIG (100 mg/ml) at an indicated dilution. Myotubes were then measured for luciferase activity at 9 
days after infection. Compared to unmodified rAAV and rAAV 587 TG MTP vectors, rAAV 588 HB MTP 
vector significantly increased resistance to human antibody neutralization at all tested IVIG dilutions ranging 
from 1:500 to 1:50 (P<0.05).   
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2.4 Discussion 
Achieving efficient dissemination of gene delivery vectors throughout the myocardium and 
skeletal musculature of an adult is a prerequisite for successful treatment of striated muscle 
diseases because it subsequently directs sufficient expression of therapeutic genes in most, if not 
all, of the diseased muscles. Distribution of vectors to the muscles of an individual through the 
circulation by adopting a simple intravenous administration is imperative for clinical therapies. 
At present this is hampered by the native tropism of viral vectors, so that no available vector 
exists for muscle tropism without involvement of nonspecific targeting after a single injection 
via the intravenous route. Toward a realistic clinical goal, novel muscle-targeting vectors are 
required.  
         As the capsid is the sole mediator during viral cell entry, AAV retargeting can be 
accomplished by genetic modification of the capsid protein. To gain a tissue-specific rAAV 
vector, single-step insertion of targeting peptide into capsid is proven to remove native tropism 
of AAV2 in combination with provision of desired tropism. Although targeted gene delivery to 
specific vascular tissue (vena cava), brain, and lung have been developed by displaying a 
selected ligand on the surface of AAV2 (243, 257), inserting a suitable peptide into the AAV 
vector for augmenting muscle-specific binding has not been described. Here, the result showed 
that a small peptide ASSLNIA, originally selected by a random phage display library (258), can 
be incorporated into the capsid of AAV2 vectors and mediate enhanced specificity of targeted 
gene transfer to myotubes. This increased selectivity of AAV transduction did not need further 
capsid modification. Inclusion of the muscle homing peptide ASSLNIA not only displayed 
adequate vector infectivity in cultured myotubes but also exhibited an extremely low binding 
affinity for non-target cell types, such as undifferentiated myoblasts, hepatocyte-derived cells, 
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and embryonic kidney cells. Besides, both engineered peptide-modified AAV vectors were 
significantly more resistant to neutralization than virus carrying wild-type AAV2 capsid in 
guinea pig anti-AAV2 serum, albeit with a decreased level of resistance to neutralization by 
human IVIG. This study is the first to genetically modify AAV muscle tropism by using an 
insertion of a targeting peptide. The study sheds light on the solution of preexisting immunity 
against AAV2 vectors during clinical applications.  
         A good knowledge of the attachment receptors of AAVs, as well as of their crystal 
structures of capsid proteins, has greatly helped progress in using the system of ligand-directed 
targeting. At least two important parameters will shape the success of peptide-incorporated 
capsids for retargeting viral vectors. The first challenge is to choose the location for insertions of 
foreign peptides. The acceptable insertion sites must tolerate insertions without affecting either 
assembly or packaging of the virus capsid and these positions allow inserted ligands to be 
exposed on the surface of virus. Meanwhile, the insertion at the chosen site can interrupt the 
interaction between virus and cellular receptors in order to diminish the natural tropism of the 
vector. The crystallographic structure of the AAV2 capsid has been unveiled recently (201). In 
this model, the capsid protein subunit contains eight antiparallel β-strands that form a barreled 
structure common in the different parvovirus genuses. Loops of variable length connect each 
strand of the β-barrel and extend outward to constitute the surface features of AAV. Alignments 
of sequences from all the parvovirus capsid proteins reveal that sequences of the β-barrel core 
are the most conserved (282). Mutations within these highly conserved regions usually abolish 
viral capsid formation (283). Conversely, sequence similarity of the loops is low. These variable 
sequence regions are allowed to present insertions. Loop GH is one of variable sequence regions 
and is required for binding to heparin. As mentioned, the position after residue 587 in the capsid 
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of AAV2 corresponding to an external loop (loop IV or GH) in the capsid could tolerate amino 
acid insertions without causing any deleterious effects on virus assembly or packaging (268). 
Consistent with previous studies, the peptide-modified vectors, 587 TG MTP and 588 HB MTP, 
represented viral titers comparable to that of unmodified virus (data not shown). In this study, the 
peptide-modified viruses were similar to the unmodified one in their ability to package a vector 
genome for efficient virion propagation. After an appropriate insertion site in the capsid has been 
chosen, the choice of targeting peptide must be made. It has been indicated that the nature of the 
inserted peptide may have important consequences on particle formation (284, 285). For example, 
peptides have fewer detrimental effects on viral yield than those containing multiple cysteine 
residues (286). On account of this, the chosen muscle-specific ligand did not possess any 
cysteines and it allowed both peptide-modified vectors to produce viral yields at reliable levels. 
The heparin-binding mutant (HBSmut) included three mutations (R484E, R585A, and R588A) 
that were located in the loop GH region, not in the β-barrel core. Thus, this mutant also resulted 
in a viral titer similar to that of unmodified vector as expected.  
         The in vitro transduction results described in this study provide proof that ligand-directed 
AAV muscle targeting displayed potential clinical value. The data showed a promising strategy 
to alter AAV2 tropism without disrupting viral replication and intracellular trafficking, since the 
peptide-modified vectors can be efficiently produced and retain their ability to direct transgene 
delivery to the nucleus of targeted C2C12 myotubes (Figure 9 and Figure 10). The insertion of a 
muscle-specific ligand into the viral capsid maintained the normal efficiency of the post-
attachment steps of the peptide-modified vectors in myotubes. These post-attachment steps are 
the downstream events required for productive infection and they include escape from the 
endosome, migration to the nucleus, and viral uncoating by virtue of vector-mediated gene 
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expression. Additionally, specificity in the delivery of therapeutic genes is the next crucial issue 
for effective gene therapy in systemic treatment of MD. Indiscriminate gene delivery to 
unwanted cell types would certainly diminish the gene dose to the targeted muscle fibers and 
would probably be harmful. Knocking out the native tropism of AAV vectors is the best 
approach to achieve cellular specificity. Transduction of peptide-inserted vectors, 587 TG MTP 
and 588 HB MTP, on undesirable cell lines proved that these ligand-expressing viruses 
demonstrate a profile of gene transfer significantly different from that of virus carrying wild-type 
capsids. Both peptide-inserted vectors had a dramatic decrease ranging from 90.67% to 99.73% 
in gene transfer efficiency compared to unmodified AAV2 when they were used to infect C2C12 
myoblasts, HepG2, HeLa, 293, and U-87MG cells (Figure 11~15). The decrease in effectiveness 
of vector-mediated gene transfer to undesired permissive cells suggests that this targeting method 
was both specific and restrictive. The PDB, SwissProt, nonredundant GenBank CDS translations, 
Spupdate and PIR data bases were used to search for the ASSLNIA sequence, but no matches 
were discovered in the previous study (258). Although the target receptor of the ASSLNIA 
peptide is not identified and it is not known whether this peptide represents a nature ligand, it 
seems clear that insertion of this muscle-specific peptide produced rAAV vectors with a 
restriction of the viral tropism to the desired myofibers. Ligand-directed muscle targeting 
remarkably improved the selectivity of targeted gene transfer in the in vitro assays. Thus, the 
peptide-engineered AAV vectors in this study give rise to the hope of transforming muscle-
specific in vivo gene transfer through systemic routes from concept to reality.  
         Apart from cellular specificity of gene transfer vehicles, avoiding elimination and 
neutralization of vectors by the host immune responses is also a critical factor which can have an 
important effect on gene therapy. Anti-CD4 and Anti-CD40 Ligand (anti-CD40L) antibodies 
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have been used to suppress T-cell activation and B-cell activation through T-cell helper function, 
respectively while CTLA4-immunoglobulin fusion protein (CTLA4Ig) has been shown to inhibit 
T-cell activation by interfering with CD28-B7 costimulatory pathway between T and B cells. 
Therefore, these treatments would be expected to block, or at least to reduce primary host 
immune responses against rAAV vectors and facilitate viral delivery of therapeutic genes. 
Transient depletion of helper T cells with anti-CD4 antibodies at the initial rAAV2 exposure 
allowed successful transgene expression following vector readministration to skeletal muscle 
(287). Similarly, treatment with anti-CD40L antibody (MR1) and a soluble CTLA4Ig at the 
primary exposure to AAV permitted repeat vector delivery in mouse lung and prevented 
production of neutralizing antibodies (288). However, it should be noticed that these treatments 
do not specifically act on viral immunity but are involved in potentially detrimental general 
immunosuppression. Moreover, these reagents were much less effective when the individual had 
undergone a secondary immune response in which a high level of neutralizing antibodies against 
wild-type AAV2 already existed (221). In order to circumvent the above obstacles, the best way 
to prevent the virus from antibody binding is to genetically modify the AAV capsid based on the 
epitope map of the capsid protein. 
         Huttner et al. demonstrated that the insertion of an integrin-specific RGD ligand (L14, 
QAGTFALRGDNPQG) after position 587 of AAV2 capsid escaped the neutralizing effects 
exerted by 13 of the 15 neutralizing serum samples and efficiently infected targeted cell lines 
(222). In accordance with this finding, it is reasonable to assume that capsid modification after 
residue 587 is not only able to alter the AAV tropism but also to generate immune escape 
variants. Therefore, the ability of AAV antibodies from guinea pig antiserum or human IVIG to 
neutralize transduction by the peptide-modified vectors was investigated in C2C12 myotubes. 
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The 587 TG MTP vector without the RXXR heparin-binding domain was significantly more 
resistant to neutralization by guinea pig antiserum than the wild-type AAV2 capsid (Figure 16). 
But it had no effect on neutralization by IVIG (Figure 18). Such results could be explained by 
differences in the affinities or frequencies of anti-AAV2 capsid antibodies between guinea pig 
antiserum and IVIG. Although 587 TG MTP vector was not neutralization resistant in an in vitro 
IVIG neutralization assay, it did display some degree of immunogenic property different from 
unmodified vector and this acquired phenotype tended to be more resistant to preexisting 
antibodies since displayed a remarkable reduction of neutralization in guinea pig serum. Besides, 
in vitro neutralization occurred via direct antibody binding of viral capsids causing virus 
sequestration, interruption of viral attachment to cellular receptors, induction of viral aggregation, 
or inhibition of viral uncoating. Neutralization mechanisms in vivo can be more complex and are 
hard to mimick by an in vitro assay. In vivo, rAAV particles are also cleared by opsonization in 
addition to antibody-mediated direct interference of viral infectivity. Both neutralizing and non-
neutralizing antibodies elicit phagocytosis and consequently enhance clearance of viral particles 
by coating virions with antibodies that also bind to Fc receptors on neutrophils and macrophages 
(289, 290). It may allow the effect of 587 TG MTP vector on IVIG neutralization to be assessed 
in vivo by the published murine model that reconstituted SCID mice with human IVIG (281). 
         More recently, a series of follow-up experiments was carried out in a dose-escalation 
clinical study of rAAV2-F.IX (Factor IX) delivered through the hepatic artery in humans with 
severe hemophilia B (223). The result indicated that T cell-mediated immunity, targeting the 
capsid of AAV2 vectors led to the destruction of transduced hepatocytes. This liver toxicity 
resulted in transient transaminitis and it limited the duration of therapeutic F.IX expression to a 
short-lived period of ~8 weeks. To further investigate this kind of cellular immune response, 
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Vandenberghe et al. evaluated activation of T cells by AAV capsids after intramuscular injection 
of vectors into mice and nonhuman primates (224). High level of T cells specific to AAV2 
capsid was observed in the AAV2-injected macaques. T cells from mice injected with hu.13, an 
AAV isolate differing from wild-type AAV2 at only two residues other than in the RXXR 
heparin-binding domain, could not respond to AAV2 capsid antigens. It suggests that the 
presence of heparin binding directly correlates with activation of capsid-specific T cells. The 
mechanism by which heparin binding associated with the activation of T cell responses to AAV2 
capsid was immediately emerged as a dendritic cell (DC) pathway. The data of binding studies 
showed that RXXR-containing vectors bound DCs whereas heparin-binding deficient variants 
did not bind as well. Since HSPG has been determined to interact with DCs and promote their 
activation (291, 292), it has been speculated that the binding of AAV2 capsid to HSPG shuttles 
the virion into a DC pathway that triggers its processing and MHC class I presentation followed 
by T-cell activation. Based on these findings, it is possible that the heparin-binding deficient 587 
TG MTP vector will not induce T-cell immunity due to the ablated heparin-binding motif. 
Enzyme-linked ImmunoSPOT (ELISPOT) can evaluate mice injected with 587 TG MTP vectors 
for activation of T cells to AAV2 capsid proteins in the future. 
         Unlike the T-cell activation to AAV2 capsid, mutations that reduced neutralization by 
human sera or IVIG do not exclusively locate in the heparin-binding domain (293). Furthermore, 
the presence or absence of heparin-binding ability of AAV2 virions is not directly correlated 
with preventing vectors from antibody-mediated neutralization because many antibody-escape 
mutants in AAVs and a number of picornaviruses occur in receptor-binding sites without 
affecting receptor binding (247). For example, the N587A mutation of AAV2 capsid lying on the 
RXXR heparin-binding site evaded antibody neutralization in human sera, but had no effect on 
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heparin binding and maintained high infectivity (293). The same phenomenon was observed in 
this study. The 588 HB MTP vector retaining the heparin-binding affinity (Figure 20 and Figure 
21 in chapter 3) dramatically reduced sensitivity to neutralizing antibodies in guinea pig 
antiserum (Figure 16) and human IVIG (Figure 18) compared to unmodified AAV2 vectors. One 
trait of the N587A mutant is that only one amino acid substitution was sufficient to avoid 
antibody neutralization. Actually, except this mutation, several single mutations, such as the 
R471A, T550A, and V708A mutants, have also been found to reduce neutralization by IVIG or 
individual human sera (293). It reveals that the precise conformational structure of capsid epitope 
is indeed required for neutralizing antibody recognition. Although the 588 HB MTP vector had 
an intact RGNR motif which did not contain any amino acid substitution, it is possible that the 
insertion of MTP peptide adjacent to the RXXR region caused capsid conformational change 
which directly interfered with neutralizing epitopes spanning residues 585 to 588 or antigenic 
determinants on neighboring loops within the threefold proximal peaks on the capsid surface. 
This induced conformational change blocked the antibody recognition and thus, conferred the 
neutralization resistance on the 588 HB MTP virus. Another explanation is that insertion of a 
targeting ligand after the RXXR motif led the 588 HB MTP vector to be able to use a different 
uptake route, which depended on an alternative cellular receptor rather than HSPG binding when 
the epitopes located in the heparin-binding motif were bound by antibodies.  
         Systemic gene delivery to only certain cell types is highly desirable, especially when the 
target cells, such as muscle fibers, are dispersed throughout the body. Taken together, these in 
vitro results indicated that the MTP-modified vectors retained their ability to transduce target 
myotubes and acquired cell targeting selectivity. Importantly, the MTP-incorporated vectors also 
exhibited the improved resistance to neutralization by antibodies against wild-type capsid. The 
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finding reported here provides us a starting point to create an efficient muscle-specific vector 
suitable for systemic delivery in human gene therapy.      
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3. DEPENDENCE OF HSPG-BINDING OF MODIFIED AAV2 VECTORS IN 
MYOTUBE TARGETING 
3.1 Introduction 
The binding of AAVs to their target cells is the indispensable step in establishing a successful 
infection. A wide spectrum of cell surface molecules have been demonstrated to participate in 
the processes of cell-virion recognition and interaction. Numerous viruses utilize cell surface 
glycoproteins, glycolipids, or proteoglycans as receptors to infect target cells. The specific 
interaction between viruses and cell surface receptors plays a key role in determining the host 
range and the tissue tropism of an AAV. AAV2 is gaining attention as a promising vector system 
for gene transfer because of its ability to achieve long-term transgene expression.  However, the 
wide distribution of its primary attachment receptor, HSPG, throughout the body hinders 
selective transduction of target tissue. Heparan sulfate is found to be associated with both plasma 
membranes and the extracellular matrix in large quantities. Heparan sulfate is present at the cell 
surface in the form of HSPGs and is a highly sulfated polysaccharide, possessing a number of 
negatively charged groups. These negative charges of heparan sulfate, therefore, interact with the 
viral proteins carrying positive charges and bridge the initial contacts between viruses and target 
cell (294). Vectors aiming to redirect the tropism of AAV2 have been produced by insertion of 
targeting peptides at the position after residue 587/or 588 of the capsid. This is likely to interfere 
with the HSPG binding of the RXXR motif on AAV2 capsid and thus, enables the targeting 
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vector to acquire novel tropism. In some cases, the HSPG binding ability of peptide-modified 
vectors is only partially affected (257) or is even restored (286, 295, 296). To investigate whether 
MTP peptide incorporation after amino acid 587/or 588 interfered with HSPG binding of 
modified AAV2 vectors, in vitro transduction assay with exogenous competing heparin and 
heparin-affinity column analysis were used to assess this. The competitive blocking experiment 
with synthesized muscle-specific ligands was further applied to examine if the transduction of 
myotubes by peptide-modified vectors was specifically mediated by the ASSLNIA peptide 
inserted at AAV capsid. 
         Peptide-specific effects on the tropism of the modified vectors had been proven. The results 
from this chapter highlighted the potential value of combined in vivo phage display (258) and the 
technology of vector capsid modification for exploitation of novel muscle targeting vectors. 
3.2 Material and methods 
3.2.1 In vitro heparin competition assay 
A total of 2x1010 genomic particles of single-stranded unmodified rAAV, rAAV 587 TG MTP, 
or rAAV 588 HB MTP vectors expressing the luciferase gene from CMV promoter were first 
incubated with or without 30 µg/ml heparin (from porcine intestinal mucosa; Sigma) in DMEM 
containing 2% HS for 1 h at 37˚C. Then, rAAV alone or rAAV-heparin mixture was added into 
C2C12 myotubes for 72 hours. Cell were next given fresh DMEM with 2% HS and were 
subsequently incubated at 37˚C until 6 days. The infected myotubes were then harvested for the 
luciferase assay. All targeted rAAV-mediated transduction experiments were performed in 
triplicate.  
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3.2.2 Heparin-binding assay 
5x1011 genomic particles of rAAV were suspended in 0.5 ml of viral suspension buffer (50 mM 
NaH2PO4, 2 mM MgCl, 2.5 mM KCl, 50 mM Hepes, 150 mM NaCl, pH 8.0) and were then 
loaded onto a 1-ml HiTrap heparin column (Amersham Bioscience) preequilibrated with 0.15 M 
NaCl and 50 mM Tris at pH 7.5. The column was further washed twice with 5 ml of binding 
buffer (10 mM NaH2PO4 pH 7.0) and eluted twice with 5 ml of elution buffer (10 mM NaH2PO4, 
1 M NaCl pH 7.0). The flowthrough, wash, and elution fractions were collected. 20 µl of each 
fraction was analyzed by DNA dot-blot assay with a CMV probe and was also subjected to 
Western blot with guinea pig anti-AAV2 capsid sera as described in chapter 2. Heparin 
dependence was verified by estimating viruses present in wash or elution fraction.          
3.2.3 In vitro peptide blocking experiment  
The competitive blocking experiment by the synthetic peptides was carried out in C2C12 
myotubes. AAV vectors and C2C12 myotubes were preincubated with 2 mg/ml of the synthetic 
muscle-specific peptide (NH2-ASSLNIA-CONH2) or the nonspecific peptide (NH2-LISNSAA-
CONH2) as control at 37˚C for an hour. Then, AAV vectors were added into C2C12 myotubes 
for 24 hours. C2C12 myotubes were washed and changed to 2% HS DMEM. After 96 hours of 
continuous incubation, the cells were harvested and analyzed by luciferase assay. 
3.2.4 Statistical analysis 
All data were expressed as mean±SEM. To test for statistical significance, unpaired Student’s t 
test was applied by one- or two-tailed test. All in vitro data were analyzed between groups and 
were considered significant when P < 0.05.  
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3.3 Results 
3.3.1 HSPG-binding dependence for peptide-modified rAAV transduction 
In a recent study, it has been shown that slow muscle fibers in newborn or 6- to 8-week-old mice 
seemed to be preferentially transduced by AAV2 vectors, while fast myofibers appeared to be 
only slightly transduced (297). Since slow myofibers have a high level of HSPG at those ages, it 
has been suggested that the ability of AAV2 to transduce myofibers correlates with the HSPG-
mediated entry pathway. However, HSPG is a molecule found on many cell types and causes the 
broad tropism of AAV2. This becomes a serious limitation for systemic muscle targeting of 
AAV2 vector. In order to provide a practical means of conquering the limitation imparted by the 
endogenous viral tropism of AAV2, specific muscle-targeted AAV vectors must be able to 
transduce muscle efficiently by adapting an alternative entry pathway without HSPG binding.  
         To determine if the insertion of MTP peptide had provided the peptide-modified mutants 
with a HSPG-independent cell entry mechanism, gene transduction assay of C2C12 myotubes 
was performed by ss rAAV CMV-Luc vectors in the presence of soluble heparin. The 
transduction of 587 TG MTP vector was not affected by heparin (P>0.05), whereas unmodified  
and 588 HB MTP vectors significantly decreased their transduction efficiency by 72.03% and 
42.25%, respectively, in the presence of heparin sulfate (P<0.05) (Figure 19).  
         These results strongly suggested that the mutant viral particles of the 587 TG MTP vector 
might be directing infection via an alternative cellular receptor. 
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Figure 19 Quantification of HSPG-independence of peptide-modified mutants 
C2C12 myotubes were infected with ss rAAV CMV-Luc vectors carrying unmodified or peptide-inserted 
capsids in the absence or presence of 30 µg/ml heparin and analyzed for gene expression to examine the 
HSPG dependence of vectors. *Indicates P<0.05 verus transduction in the absence of heparin.    
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3.3.2 Heparin-binding affinity of modified rAAV vectors 
The previous result was able to show, that the insertion of the muscle-specific ligand after 
residue 587 of AAV2 capsid enabled the vector to infect myotubes in a HSPG-independent 
manner. Another useful way for detection of heparin-binding affinity of these mutants is by 
heparin column chromatography. Here, a small-scale heparin-binding assay, by loading 5x1011 of 
each mutant ss rAAV CMV-Luc vector onto a heparin column, was applied. After extensive 
washing of the heparin column, bound rAAVs were eluted in 1 M NaCl. Viruses in the collected 
fractions were detected by DNA-dot blot assay with CMV probe and by Western blotting using 
guinea pig anti- AAV2 serum. 
         As expected, viruses containing a wild-type capsid had a high affinity for the heparin 
column, and were solely found in the eluted fraction (Figure 20 and Figure 21). The 588 HB 
MTP rAAVs also displayed heparin-binding ability similar to unmodified vectors since the 
majority of the vector was found in the column elution and negligible amounts of virus were 
found in the unbound wash. In marked contrast to unmodified and 588 HB MTP vectors, the 587 
TG MTP viruses were substantially detected in the column wash, the unbound fraction. The 
HBSmut vectors were essentially undetectable in the elution and some of them appeared in the 
flow-through.   
         These results were consistent with gene transduction studies in the presence of soluble 
heparin as competitor. The insertion of ASSLNIA targeting peptide at position 587/or 588 of the 
AAV2 capsid could determine the heparin-binding phenotype of vectors.  
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Figure 20 Heparin-affinity column analysis coupling with DNA dot-blot assay 
5x1011 of unmodified or peptide-inserted viruses were loaded onto a prepacked and equilibrated 1 ml heparin 
column. Viral particles appeared in the flow-through, wash, and elution fractions were then detected by DNA 
dot-blot with CMV probe. Plasmid control was made by pCMV-Luc plasmid in serial two-fold dilutions. 
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Figure 21 Western blot applied for the heparin-affinity column analysis 
The fractions from the heparin-affinity column analysis were analyzed by Western blot using guinea pig anti-
AAV2 serum. The positions of VP1, VP2, and VP3 are indicated. I: Input; F: Flow-through; W: Wash step; E: 
Elution  
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3.3.3 Influence of synthesized blocking peptide in rAAV transduction 
After showing that 587 TG MTP mutant infected myotubes independent of heparin sulfate, it 
was further investigated whether the peptide-modified 587 TG MTP vector performed heparin-
independent gene delivery via the introduced muscle-specific ligand. This experiment can 
evaluate the targeting fidelity of the chosen homing peptide for matured myofibers. 
         To ensure that the 587 TG MTP targeting is mediated by the ASSLNIA peptide insert, the 
transduction efficiency of peptide-incorporated mutants in C2C12 myotubes was determined in 
the presence or absence of the cognate peptide (Figure 22). Gene transduction mediated by the 
587 TG MTP vectors was significantly inhibited (47.30%) in the presence of 2 mg/ml free 
ASSLNIA peptide (P<0.05). Moreover, this substantial competitive inhibition by synthesized 
muscle-specific targeting peptide was not observed in the transduction of 587 TG MTP vector 
with a nonspecific control peptide containing amino acid sequence LISNSAA.   
         Taken together, synthesized MTP peptide exerted significant inhibition on the 587 TG 
MTP mutant rAAV2-mediated gene transduction and this blocking effect on viral infection could 
not be carried out by a nonspecific peptide. This shows that the muscle-specific ligand, 
ASSLNIA, ensures peptide-modified rAAV vector to gain a novel tropism that facilitates muscle 
targeting.    
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Figure 22 Competitive inhibition in myotube transduction of peptide-inserted rAAVs by the cognate peptide 
 
C2C12 myotubes were infected with ss rAAV CMV-Luc vectors in the presence or absence of synthesized free 
peptides. Level of gene transduction efficiency of peptide-modified vector and unmodified rAAV virus were 
compared by evaluating luciferase expression.* P<0.05 vs value in the absence of peptide.    
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3.4 Discussion 
Heparan sulfate is present ubiquitously in the body and it can be displayed on the cell surface as 
HSPG. The structure of HSPG consists of a core protein and heparan sulfate polysaccharide side 
chains. HSPGs are required for many biological processes, including embryonic development, 
blood coagulation, and wound healing (298, 299). In addition to these processes, a large amount 
of evidence about the involvement of HSPG in assisting viral infections has emerged in recent 
years. More importantly, HSPG is gaining increasing attention in AAV vector delivery systems 
because it is the primary receptor for AAV2 cell entry and the expression of HSPG in various 
tissues severely impedes the efficiency and specificity of vector targeting. Therefore, 
incorporation of the muscle-specific ligand into a particular region of the AAV2 coat protein 
needs to ablate viral attachment to heparan sulfate present in the extracellular matrix and on the 
cell membrane. 
         Experimental analysis of peptide-inserted mutants in their potential capability of heparin 
binding was successfully performed and was a way to predict the specific muscle-targeting 
efficiency of modified vectors in systemic delivery prior to the in vivo mouse model being 
carried out. In gene transduction experiments, the peptide insertion after amino acid 587 of 
AAV2 capsid provided vector HSPG-independence in targeting gene delivery because the 
transduction of 587 TG MTP vector in myotubes was not suppressed by soluble heparin (Figure 
19). Consistent with gene transduction data, most of the mutant viruses with ligands incorporated 
after position 587 were recovered in the wash fraction, albeit minor amounts of the virus 
contained in the eluate (Figure 20). Conversely, the peptide incorporation after residue 588 
reserved the RXXR motif of the capsid and showed that the vector retained the gene transduction 
efficiency relying on viral attachment via HSPG (Figure 19, Figure 20, and Figure 21). It is 
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apparent that the HSPG dependence of 588 HB MTP vector is still less than that of unmodified 
rAAVs since soluble heparin enhanced its inhibition by 29.78% in unmodified rAAV2-mediated 
transduction (Figure 19). These findings demonstrated that the muscle-specific vector generated 
by the incorporation of MTP after residue 587 eliminated the endogenous tropism of AAV2 and 
obtained the muscle targeting specificity from introduced peptide (Figure 22). 
         Viral binding to HSPG is the result of electrostatic attraction between a cluster of positively 
charged amino acids on viral coat protein and negatively charged sulfate groups from heparan 
sulfate. Spatial orientation of basic residues rather than sequence proximity is considered as an 
important factor in determining heparin-binding affinity (300). So far, three heparan sulfate 
consensus-binding sequences have been identified in several receptors and viruses (270, 301). 
Two of them are linear binding sequences, XBBXBX and XBBBXXBX (where B is a basic 
amino acid, including His, Lys, or Arg, and X is any amino acid). The other one is a 
conformation-dependent sequence, TXXBXXTBXXXTBB (T is a turn). Regions including these 
clusters tend to be sensitive to spacing changes. Heparin-binding domains of viral particles are 
usually located at the capsid surface and form a flat pocket with a positive charge. In AAV2, the 
basic residues K532, R484, and R487 of one subunit surround R585 and R588 from the loop of 
another subunit (256). A mutagenesis study identified that mutation of one of these five basic 
residues interfered with heparin binding and decreased viral infectivity (250). It suggests that this 
structure is the basic patch on AAV2 capsid required for heparin binding and its formation needs 
the correct subunit interaction and assembly. The peptide insertion site after amino acid 587 is 
part of the basic patch and is located on the capsid surface in the “finger-like” projections 
surrounding the threefold axis. The structure analysis data in the previous chapter were 
consistent with the results from gene transduction assays with the heparin competitor (Figure 19) 
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and provided solid evidence of the differences in heparin-binding sensitivity between 587 TG 
MTP vector and 588 HB MTP virus.  
         The insertion of peptides after residue 587 of AAV2 capsid was originally designed to 
disrupt the HSPG binding of AAV2 and to expose the incorporated ligand to an alternative cell 
receptor for viral cell entry. In fact, several reports have indicated that this insertion site did not 
exclusively confer the heparin-binding independence of peptide-inserted vectors (257, 286, 295, 
296). A recent study has shed some light on this and shows that the amino acid content of 
peptides plays an important role in determining the heparin-binding affinity of modified AAVs 
(302). It suggested that the insertion of peptides with bulky amino acids is prone to result in the 
spatial separation between R585 and R588 or sterically blocks the heparin-binding ability. If the 
inserted peptide consists of small residues, the insertion effect could be less detrimental and the 
structure of the heparin-binding motif remain functional. The insertion of a peptide having basic 
residues could lead to the production of an HSPG binding phenotype by reconstituting a heparin-
binding domain in combination with one of the original arginine from the RXXR motif or by the 
heparin sulfate consensus-binding sequences present at the inserted ligand. According to these 
findings, the inserted muscle-specific ligand with the linker sequences on 587 TG MTP mutant 
did not include any basic residues or the consensus heparin-binding domain. This chosen peptide 
sequence prevented 587 TG MTP from generating a new HSPG binding motif after peptide 
insertion. In addition, the inserted peptide of the 587 TG MTP virus had amino acid up to 12 
which might cause the invasive effect like the damage from bulky peptide in heparin binding. 
         The molecular modeling data also showed that both peptide-modified vectors, 587 TG 
MTP and 588 HB MTP, appeared to have the inserted MTP forming the loop-like structure 
extending to the outside surface of VP3 monomer (Figure 23). This feature allowed the 587 TG 
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MTP vector to acquire specific muscle targeting from peptide insertion exposed to the surface of 
the capsid subunit (Figure 5). 588 HB MTP mutant is likely a better vector with the dual 
phenotype. Since the gene transduction of 588 HB MTP vector was not suppressed by soluble 
heparin as much as that of unmodified rAAVs in the presence of heparin (Figure 19), it implied 
that the incorporated ligand of 588 HB MTP could contribute to viral transduction which was not 
inhibited by heparin. Moreover, the transduction of 588 HB MTP vector in C2C12 myotubes was 
inhibited by the synthesized ASSLNIA peptide up to 58.75% albeit with statistical significance 
P>0.05 (Figure 22).  
         In order to direct rAAV vector to a specific tissue following intravenous administration, the 
tropism-modified vector will require diminution of its natural tropism and it presents a ligand 
that will recognize a cellular receptor accessible through the circulation and selectively expressed 
in the organ or tissue of interest. Here, it has been shown that the 587 TG MTP vector mediated 
HSPG-independent muscle transduction in vitro. The 587 TG MTP virus is suitable for systemic 
gene transfer in humans. 
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Figure 23 Ribbon representations of VP3 subunits from unmodified, 587 TG MTP, and 588 HB MTP rAAVs 
The structures of all VP3 subunits were merged by using Swiss-Model. 
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4. INCORPORATION OF MUSCLE-SPECIFIC LIGAND INTO CAPSID RETARGETS 
AAV2 TO STRIATED MUSCLE AFTER SYSTEMIC DELIVERY 
4.1 Introduction 
The ability to target specifically the striated muscles in the body via the systemic circulation 
would be of great clinical significance for treatment of muscular dysfunction. Several vector 
systems, such as retroviruses, Ads, and AAVs, have been applied to deliver the therapeutic gene 
to muscle. However, viral vectors derived from retrovirus have several disadvantages, including 
their inability to transduce postmitotic cells (e.g., myofibers), the low gene insert capacity, and 
the risk of insertional mutagenesis (303-305). Ads are able to infect both mitotic myoblasts and 
postmitotic immature muscle fibers, but their utilizations are restricted by immunological 
problems and transduction of myofibers in a maturation-dependent manner (306). In contrast to 
Ads, AAV vectors enable conferment of sustained transgene expression for in vivo gene therapy 
to skeletal muscle as they are less immunogenic. AAV8 has been shown to be able to achieve 
systemic transduction of skeletal and cardiac muscles in neonatal and adult mice (148). This 
attributes to the capability of AAV8 in penetrating the biological barrier imposed by the blood 
vessel of the muscle tissue. Unfortunately, like other AAV serotypes, AAV8 possesses poor 
targeting selectivity as same as other AAV serotypes. Therefore, the nonspecific targeting of 
AAV vectors still remains a major hurdle facing the application of systemic rAAV-mediated 
gene transfer to skeletal muscle in humans. The modification of viral capsids to retarget vectors 
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has emerged as an attractive route to create ideal viral vehicles for defined applications. The 
results from in vitro studies showed the efficiency and selectivity of peptide-inserted vectors in 
myotube targeting. First, the data demonstrated that these peptide-modified vectors maintained 
their myotube transduction ability. Second, peptide-engineering AAVs decreased their 
transduction in non-muscular control cell lines, such as HepG2, HeLa, and 293 cells. Third, the 
peptide-modified AAV 587 TG MTP vector did not require the heparin-dependent mechanism 
for muscle targeting. These findings indicate that the muscle-targeting peptide isolated by in vivo 
phage display could be incorporated into AAV2 capsids and provide enhanced transduction 
selectivity in vitro. Thus, the targeting property of peptide-modified vectors was further 
evaluated through side-by-side comparison of the unmodified vector and peptide-inserted 
mutants by direct intramuscular and intravenous vector delivery.  
4.2 Material and methods 
4.2.1 In vivo characterization of vectors via intramuscular delivery 
Eight-week old ICR-CD1 adult male mice were purchased from Charles River. Fifty µl of viral 
solution, containing 2.5x1010 genomic particles of ss rAAV CMV-Luc vector with unmodified 
capsid or peptide-modified capsid, was injected into the tibialis anterior (TA) muscle of mice. 
Four weeks following injection, the mice were sacrificed. The TA muscles were harvested and 
frozen in liquid nitrogen. After homogenization of muscle tissues, the protein concentration was 
determined and the luciferase assay was performed. Luciferase activity was depicted in relative 
light units (RLU) per milligram of protein. 
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4.2.2 In vivo characterization of vectors via intravenous delivery 
Mice were injected intravenously via a tail vein with a viral solution containing 9x1011 genomic 
particles of ss rAAV CMV-Luc. After four weeks, the mice were sacrificed and representative 
organs (brain, heart, liver, skeletal muscles, kidney, testis, and spleen) were harvested for the 
luciferase assay. Luciferase activity was expressed as relative light units (RLU) per milligram of 
protein. 
4.2.3 Vector biodistribution in systemic delivery 
Mice were treated intravenously via a tail vein with ss rAAV CMV-Luc vectors at 9x1011 
genomic particles/mouse. Mice were then sacrificed and organs (brain, heart, liver, skeletal 
muscles, kidney, testis and spleen) were harvested four weeks after intravenous injection. 
Genomic DNA was extracted from organs using DNeasy kit (Qiagen Inc). Relative numbers of 
vector genome were determined using real-time PCR. A luciferase quantification standard curve 
was generated from serial dilutions of the pAAV CMV-Luc plasmid by use of SYBR green with 
100 pmol/µl sense 5’-GACGCCAAAAACATAAAGAAAG-3’ and antisense 5’-
AGGAACCAGGGCGTATCTCT-3’ Luc primers. 200 ng genomic DNA was used for PCR 
amplification and the PCR products were quantified using TaqMan data analysis software 
(Applied Biosystems). All data were expressed as vector copies per µg genomic DNA. The 
following PCR reaction conditions were used: denaturation, 95˚C for 2 min; 40 cycles of 
amplification, 95˚C for 15 sec, 60˚C for 1 min. 
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4.2.4 Statistical analysis 
All in vivo data were analyzed using the nonparametric Mann-Whitney U test. Data were shown 
as mean±SEM.  
4.3 Results 
4.3.1 In vivo transduction of skeletal muscle by local delivery of rAAVs  
Many gene therapy applications have used rAAV2-based vectors for gene transfer because 
rAAV2 has been demonstrated to lead to stable gene expression in muscle for up to several years 
(307, 308). To test if the peptide-modified vectors could maintain the efficiency of muscle 
transduction as well as unmodified rAAV2 in vivo, TA muscles of mice were directly injected 
with unmodified vectors or peptide-inserted mutants encoding luciferase from CMV promoter.     
         When the administered viral dose was at 2.5x1010 genomic particles per muscle, 588 HB 
MTP vector yielded higher transduction than rAAV vector carrying wild-type capsid (Figure 24).  
However, 587 TG MTP vector demonstrated decreased muscle targeting by 44% after 
intramuscular delivery compared to muscle transduction mediated by unmodified rAAV vectors.  
         Theses in vivo results from local injection were similar to the in vitro myotube transduction 
data (Figure 9).  
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Figure 24 Intramuscular delivery of peptide-modified rAAV vectors in mice 
Luciferase activities were obtained from the TA muscles of mice injected with 2.5x1010 genomic particles of ss 
rAAV CMV-Luc vector carrying wild-type or modified capsids 4 weeks before examination (n=4 TA muscles 
for each vector tested).    
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4.3.2 In vivo rAAV-mediated muscle transduction by systemic delivery 
Systemic muscle targeting of peptide-modified vectors after intravenous administration was next 
examined at the whole-body level in eight-week old adult mice. The major organs of mice were 
analyzed for luciferase activity four weeks after administration through the tail vein of 9x1011 
vector genomes of rAAV containing a CMV-Luc expression cassette.  
         rAAV 587 TG MTP demonstrated higher muscle and heart targetings than unmodified 
rAAV2. 587 TG MTP vector showed a 2.18-fold increased transduction compared to unmodified 
virus in the diaphragm (Figure 25), and increased at least 23-fold transduction of the heart 
(Figure 26). Peptide-modified 587 TG MTP vector provided transduction of quadriceps at levels 
2.85-fold greater than that obtained using unmodified vector. Moreover, the AAV 587 TG MTP 
had significantly reduced transduction of lung, spleen, and brain (Figure 27). In contrast, rAAV 
588 HB MTP had reduced transduction in most organs, and transduction of quadricep muscles 
and heart was 0.9-fold and 0.8-fold that of unmodified vector respectively (Figure 25 and Figure 
26).  
         However, expression from the CMV promoter had shut off in the liver as was also 
observed in previous studies (147). The vector genomes of peptide-modified AAVs in the liver 
had to be determined by real-time PCR. Although CMV promoter had shut off in the liver, the 
luciferase activities of rAAV 587 TG MTP and rAAV 588 HB MTP in the liver were lower than 
that of unmodified rAAV2 (Figure 27).   
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Figure 25 Luciferase activities in muscles after systemic rAAV administration 
9x1011 vector genomes of ss rAAV CMV-Luc were delivered into adult mice through a tail vein injection (n=5 
for unmodified rAAV2 vector, n=6 for 587 TG MTP vector, n=5 for 588 HB MTP vector). Four weeks after 
injection, muscle tissues were harvested for the luciferase assay. *P<0.05 vs unmodified rAAV2 vector. 
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Figure 26 Luciferase activities in mouse hearts after systemic delivery of peptide-modified vectors 
9x1011 vector genomes of ss rAAV CMV-Luc were delivered into adult mice through a tail vein injection (n=5 
for unmodified rAAV2 vector, n=6 for 587 TG MTP vector, n=5 for 588 HB MTP vector). Four weeks after 
injection, mouse hearts were harvested for luciferase assay.   
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Figure 27 Luciferase activities in non-muscle organs after systemic delivery of peptide-modified vectors 
 
9x1011 vector genomes of ss rAAV CMV-Luc were delivered to adult mice by a tail vein injection (n=5 for 
unmodified rAAV2 vector, n=6 for 587 TG MTP vector, n=5 for 588 HB MTP vector). Four weeks after 
injection, mouse hearts were harvested for the luciferase assay. *P<0.05 vs unmodified rAAV2 vector.  
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4.3.3 Biodistribution profile of peptide-modified rAAV in adult mice 
In addition showing luciferase expression in the major organs of mice injected with peptide-
modified vectors, the vector biodistribution in organs was further determined by real-time PCR. 
The SYBR green quantitative PCR was performed on these collected tissues from injected adult 
mice and it confirmed whether the increase of transgene expression in the heart and skeletal 
muscles were attributable to an increase of vector genomes in detected tissues.   
         As predicted, systemic infusion of unmodified rAAV vectors to adult mice resulted in 
accumulation in the liver of much lower levels than in other tissues (Figure 29). Quantification of 
copy number of virions in the liver showed that rAAV 587 TG MTP decreased its liver 
transduction by 44.51% compared to unmodified rAAVs (Figure 29). In addition, 587 TG MTP 
vector exhibited decreased transduction of the lung, spleen, and brain (Figure 28). The number of 
viral particles in the heart increased from 0.96±0.45 vector copies/µg tissue genomic DNA with 
unmodified rAAV to 7.28±3.91vector copies/µg tissue genomic DNA with rAAV 587 TG MTP 
(Figure 28). rAAV 587 TG MTP-infused animals also showed the increase of vector genome in 
most examined skeletal muscles, including diaphragm, quadriceps, and tibialis anterior.  
         The real-time PCR results were quite consistent with the luciferase data. Both experiments 
demonstrated that peptide-modified 587 TG MTP vector simultaneously detargeted rAAV from 
non-muscular organs and retargeted it to striated muscles in systemic delivery.  
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Figure 28 rAAV genome distribution after intravenous delivery 
 
9x1011 genomic particles of rAAV were delivered to 8-week old mice via tail vein injection (n=5 for 
unmodified rAAV2 vector, n=6 for 587 TG MTP vector, n=5 for 588 HB MTP vector), and vector distribution 
was quantified by real-time PCR in all major organs one month after delivery. P<0.05 vs unmodified rAAV2 
vector. 
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Figure 29 Quantify hepatic rAAV genomes after intravenous delivery 
 
9x1011 genomic particles of rAAV were delivered to 8-week old mice via tail vein injection (n=5 for 
unmodified rAAV2 vector, n=6 for 587 TG MTP vector, n=5 for 588 HB MTP vector), and viral particles in 
the liver were quantified by real-time PCR one month after delivery. 
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4.4 Discussion 
The systemic delivery of therapeutic genes to striated muscle will require rAAV vector with an 
outstanding affinity for muscle fibers. The targeting specificity of rAAV is not only in line with 
the safety of gene therapy, but also is the major factor that affects the transduction efficiency of 
vector in the tissue of interest. A vector capable of efficiently targeting a specific tissue has 
important benefits in human gene therapy. One advantage is to obtain a lower established 
effective dose. Less viral dose could be used for therapeutic applications in humans. This is very 
significant since developing methods to scale up the production of rAAV vector have met with 
difficulty. An additional benefit is that a lower effective dose would increase the overall safety of 
the rAAV treatment by diminishing the amount of viral capsid protein in the body because it has 
been proven that viral capsid from AAV potentially elicits an immune response harmful to the 
therapy (224). Although integration of rAAV genomes rarely occurs in host cells (219), a 
decrease in the total amount of delivered vector would further reduce the chance of host genome 
integration and facilitate an increase of overall safety in clinical use of rAAV vectors. Therefore, 
the ultimate goal of this project was to develop an ideal clinical gene transfer vector for the 
systemic treatment of diseases affecting the heart and skeletal muscle.  
         This report characterized the behavior of the rAAV2 capsid incorporated with a muscle-
specific ligand in its ability to transduce myofibers in vivo through a single intravenous 
administration. In contrast to the unmodified capsid, the inserted muscle-homing peptide directed 
rAAV2 vector to be suited for gene delivery to the heart and skeletal muscle via systemic 
delivery. As demonstrated in this chapter, the small differences of the insertion site on capsid and 
the linker sequence used in the context of the MTP insertion dramatically altered vector behavior 
in vivo.  
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         Upon tail vein injection, the in vivo data clearly showed that 587 TG MTP vector was much 
better than 588 HB MTP vector for striated muscle transduction (Figure 25 and Figure 26). 
Compared to unmodified rAAV, 588 HB MTP vector only had slight increase in the heart and 
quadricep transduction (Figure 25 and Figure 26), but decreased its accumulation in most 
analyzed tissues including both muscle and non-muscle tissues (Figure 25 and Figure 27). 
Importantly, the capsid modification from rAAV 587 TG MTP was able to retarget the vector to 
the heart and most tested skeletal muscles and it simultaneously enabled the virus to detarget the 
liver, lungs, spleen, and brain. The CMV promoter can produce a high level of transgene 
expression. However, CMV promoter-driven gene expression lasts for only a few days at high 
levels. Moreover, CMV promoter has been shown to be inactivated in muscle tissue after 
implantation of primary myoblasts transduced with retroviral vectors containing CMV-canine 
factor IX expression cassette in mice (309). This is the reason that the luciferase activities of 
mouse skeletal muscles were low after intravenous delivery of rAAV vectors (Figure 25). 
Therefore, it would be valuable to choose a muscle-specific promoter, or sacrifice mice at 24 
hours after infusion for examining systemic vector targeting. 
         In vector biodistribution analysis, 587 TG MTP vector produced a heart-to-liver ratio of 
0.014816, and for the unmodified rAAV2 the ratio was 0.001086. Thus, there was a 13.64-fold 
improvement in the cardiac delivery with 587 TG MTP vector. During the respiratory cycle, 
diaphragm movement is an essential requirement. Since the body relies so much on the 
diaphragm for respiratory function, the diaphragm becomes the second most important muscle in 
the body after the heart. However, many disease processes ultimately cause diaphragm 
dysfunction. Therefore, a systemically delivered vector is necessary to efficiently target the 
diaphragm. The targeting ability of 587 TG MTP vector to diaphgram was assessed from the 
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real-time PCR results (Figure 28). The vector genome copy of 587 TG MTP vector was 4.2x105-
fold improved in diaphgram compared to unmodified rAAV2 (P<0.05). The mechanism of the 
enhanced diaphgram targeting by 587 TG MTP vector is unclear. 
         Although 587 TG MTP vector was superior to 588 HB MTP vector in muscle transduction 
after systemic delivery, 588 HB MTP vector demonstrated higher infectivity in intramuscular 
injection compared to unmodified and 587 TG MTP rAAVs (Figure 24). Furthermore, 588 HB 
MTP has shown more resistance in escaping preexisting humoral immune responses (Figure 16, 
17, and 18). Because muscle fibers are abundant and allow gene transfer with relatively 
noninvasive procedures, they have been utilized to express and secret biologically active gene 
products that are normally not produced by this tissue (310, 311). The findings from this study 
implied that 588 HB MTP vector might be a good candidate to deliver therapeutic gene encoding 
secretory protein when local delivery is needed for a treatment.    
         All in vivo data has been tested for statistical significance using the Mann-Whitney test. 
The Mann-Whitney test (also named the rank sum test) is a nonparametric test that compares two 
unpaired groups. As sample numbers increase, a normal approximation is used for the hypothesis 
test. The approximation to the normal distribution is best when both groups have sample 
numbers equal to or greater than 10. In this study, the number of mice in each vector group was 
only five or six. This is the possibility that most in vivo data did not have the statistical 
significance with P<0.05. However, it could be overcome by increasing the sample number of 
mice for the systemic delivery of rAAV. 
         This study has confirmed our ability to rationally design and genetically engineer tropism-
modified AAV vectors for selective delivery of genes to the whole-body muscle in vivo.    
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5. OVERALL DISCUSSION 
Gene therapy holds promise for the treatment of MDs since earlier studies have shown that 
expression of full-length dystrophin in muscles of transgenic mdx mice can eliminate the 
morphological and immunohistological symptoms of MD without toxicity (121). Various viral 
vectors have been made to deliver the therapeutic genes into the desired tissues. In the late 
1990’s, several reports demonstrated that AAV vectors can infect mouse muscles at surprisingly 
high efficiencies after a simple intramuscular injection (133, 311, 312). These findings made 
muscle-directed gene therapy a realistic application. Since AAV vectors allow packaging 
transgene less than 4.5 kbs, several approaches, such as minigene, exon-skipping, and split AAV 
vectors, have been developed to overcome this packaging size-limitation for the AAV-mediated 
delivery. However, transfer on a large amount of vector DNA into muscle by multiple 
intramuscular injections is impractical. Therefore, systemic delivery of AAV vectors by a single 
intravenous administration is the most effective method to deliver sufficient amount of 
therapeutic genes to muscle for the treatment of MD. Unfortunately, AAV vectors are 
transported poorly across vascular endothelium even when delivered by high hydrostatic 
pressure (313). Current techniques for gene delivery to muscle through blood transportation 
involve complex surgical procedures under anesthesia (255, 314, 315) and are still not feasible 
for whole-body vector delivery. Gregorevic et al. (147) showed a way to solve this problem by 
injecting AAV6 vector together with VEGF into the bloodstream of mice. This VEGF approach 
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efficiently achieved whole-body transduction of a desired gene into the heart and skeletal 
muscles. Wang et al. (148) also demonstrated that AAV8 could be utilized for efficient global 
muscular gene delivery by the intravascular route. But both approaches had a problem. In the 
systemic gene delivery through intravenous injection, AAV vectors primarily transduce in the 
liver with a broad tropism. Furthermore, transfer of a gene into unwanted nonmuscular tissues 
decreases the efficacy of the therapeutic effect of AAV-mediated transgene expression and raises 
the safety concerns about the potential increase of germline transmission of unwanted gene. 
Developing a vector that could specifically target dispersed skeletal muscles of an adult 
organism by systemic administration is essential for disease, like MD.  
        At present, at least three targeting methods are available for directing the expression of a 
transgene into a specific tissue. These methods include physical targeting, transcriptional 
targeting, and biological targeting. The physical gene delivery method is involved in injection of 
biodegradable microspheres or microbubbles with delivery vectors to improve the efficiency of 
gene transfer (316, 317). Transcriptional targeting approach involves the use of tissues-specific 
promoters to create vectors that express transgenes selectively (318, 319) while the biological 
vector targeting method utilizes modification of viral capsid proteins (320). Since the use of 
tissue-specific promoters is well-established for selective gene expression, explorations into 
capsid modification for specific gene delivery are still in their initial stage. In the study described 
here, the biological targeting through modification of viral coat proteins was carried out for the 
development of an efficient and muscle-specific targeting vector. AAV 2 was chosen for 
engineering its specific muscle targeting because it has been well-characterized for many years. 
HSPG is identified as the primary receptor of AAV2. AAV2 has been shown a broad tropism 
since HSPG widely exists in various tissues. Recently, several studies have shown that short 
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peptide sequences encoding specific receptor ligands could be incorporated into AAV capsid as a 
way to change vector tropism. Specific sites on AAV capsid that can tolerate the insertions of 
small exogenous peptides have been identified by a series of insertion mutants spanning the 
capsid protein of AAV vector (266). Identified positions at amino acid residues 139, 161, 459, 
584, and 587 are capable of tolerating peptide insertions of up to 15 amino acids without 
affecting the viral yield in most cases. The insertion of the angiogenic vascular targeting motif 
NGR on AAV2 capsid mediated an altered tropism toward cells expressing the NGR receptor 
CD13 which is presented in angiogenic vascular culture and in many tumor cell lines (286). 
Based on the other findings, the genetic incorporation of endothelium-specific peptide SIGYPLP 
into the position after amino acid 587 of AAV2 capsid significantly enhanced transduction of 
mutated AAV in human vascular endothelial cells as compared to AAV carrying wild-type 
capsid (321). In contrast, SIGYPY-modified AAV2 had much lower reporter gene expression 
than wild-type AAV2 in both human vascular smooth muscle cells and human hepatocytes. 
Nicklin et al. (321) also indicated that the transduction of endothelial cells by SIGYPLP-
modified AAV2 was independent of heparin binding. As expected, peptide-modified AAV2 
vectors carrying ASSLNIA ligand enhanced the vector targeting at the heart and skeletal muscles 
after a single intravenous administration. Interestingly, 588 HB MTP vector retaining heparin-
binding ability has significantly less enhancement of striated muscle targeting via systemic 
delivery as compared to 587 TG MTP vector without a heparin-binding motif (Figure 25 and 26). 
It is possible that 588 HB MTP vector finds it easy to be docked in the extracellular matrix since 
a high level of HSPG is also present in the extracellular matrix. Another possibility is that the 
incorporation of a specific ligand with the different linker sequences might lead AAV to enter 
the target cell through a different coreceptor. 
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         Our studies have demonstrated an efficient and selective gene transfer to the heart and 
skeletal muscles systemically which has important implications with regard to the development 
of a muscle-specific AAV vector for clinical application. The unwanted hepatic tropism of AAV 
is the main concern for decreasing the muscle targeting efficiency after systemic delivery. Based 
on the data described in this study, peptide-modified 587 TG MTP vector reduced its liver 
targeting by 44.51% as compared to unmodified rAAV2 virus (Figure 29). In addition to 
preventing vectors from docking in the liver, an ideal muscle-specific AAV vector also needs to 
eliminate its broad tropism. In our study, ligand-inserted 587 TG MTP vector significantly 
decreased its targeting to other tissues, like lung, spleen, and brain (Figure 28). Unlike previous 
studies, the peptide-modified vector described here not only increased the muscle targeting 
ability but also provided a remedy for vector delivery to nonspecific tissues. Moreover, peptide-
incorporated AAVs confer viral resistance to antibody neutralization for long-term gene 
expression (Figure 16, 17, and 18). The peptide-inserted vectors provide an important tool on the 
treatment of muscle diseases. 
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6. FUTURE STUDIES 
Targeted efficient gene delivery specifically to muscle using a systemic route is a difficult task 
because muscle is an abundant tissue dispersed throughout the body. So far, this study showed 
specific muscle targeting in mice by ligand-directed gene delivery. Although this initial success 
suggests that it will be possible to apply this modified vector system for human application, a 
previous study indicated that a peptide isolated by phage display decreased its targeting effect 
when incorporated into AAV capsid (243). This might be due to the fact that peptide 
conformation is changed in the viral protein context. Therefore, the selection of specific ligands 
for muscle targeting may be more practical if the AAV display library (244, 247, 248) is 
established to screen the random peptide pool in primary human myotubes. In recent years, DNA 
shuffling and error-prone PCR have been developed to provide large viral library diversity for 
AAV screening for specific purposes (245, 246). These technologies not only produce the AAV 
clone with the desired feature, but also are a powerful way to explore the functional domain of 
AAV capsids from different serotypes. They should also be useful in isolating the AAV clone 
perfect in systemic muscle targeting. 
         The results from this study showed that the residual hepatic tropism was still observed in 
peptide-modified vectors. It will be important and essential to identify the receptor exclusively 
expressed in mature myotubes. New gene profiling methods, such as serial analysis of gene 
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expression (SAGE), will need to be performed in order to identify suitable muscle receptors for 
targeted gene delivery.  
         Before these peptide-modified vectors are applied clinically in humans, they should be 
tested in a mouse disease model. It would be interesting to see if this vector system still retains 
its targeting capability in the setting of a pathological process ongoing in muscle. The other 
consideration is that this MTP peptide was selected from mouse (258), not human muscle cells. 
Therefore, this muscle-specific ligand would need to be tested in primary human myotubes.  
         In this study, DNase-resistant vector genomes of HBSmutMTP mutant were not detectable 
by dot-blot assay. The A20 antibody performed in A20 enzyme-linked immunosorbent assay 
(ELISA) specifically binds to intact particles including assembled, empty or full genome-
packaged, AAV2 virions, but not to single capsid proteins (322, 323) while the quantitative real-
time PCR is approximately 40-fold more sensitive than the nonradioactive dot-blot assay (266). 
In the future, it will be interesting to address whether HBSmut MTP mutants have a defect in 
viral assembly or genome packaging by a combination of A20 ELISA and real-time PCR assay. 
For example, a mutant causing the production of empty particles will be positive for the 
synthesis of AAV virions by A20 ELISA and negative by real-time PCR assay. If both the A20 
ELISA and quantitative real-time PCR assays show positive results, it means that the mutant 
vector can propagate intact viral particles containing vector genomes. It would likely indicate 
that the vector produced a low viral yield. To understand the mechanism causing HBSmut MTP 
mutant deficiency in viral production will help us to perform the more rational design for 
generating modified AAV vectors with specific tropism.     
         In contrast to the infectivity of peptide-modified vectors, the heparin-binding mutant 
(HBSmut) generated intact virions that protected the viral genome from DNase digestion (data 
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not shown), but failed to infect C2C12 myotubes and all tested non-target cell lines (Figure 9, 10, 
11, 13, and 14). In an effort to determine the capsid protein composition of the HBSmut mutant, 
a Western blot was carried out on the cesium chloride-purified virus (Figure 8). By Western blot 
analysis this heparin-binding mutant appeared to assemble the virion with the same 
stoichiometry as wild-type virions. The unmodified and HBSmut viruses showed similar 
amounts of VP3. The amounts of VP1 and VP2 from HBSmut virions were also nearly 
equivalent to those of wild-type viral particles. The reason for turning this fully assembled 
mutant noninfectious is thought to be a loss of heparin binding. However, it is possible that the 
newly acquired tropism of HBSmut virus was not discovered in the limited number of 
experimental cell lines tested in in vitro transduction assays. Since a double mutation of the 
heparin-binding motif at R484 and R585 resulting in a severe defect for heparin binding strongly 
reduced transduction of the liver and enabled increased efficiency of cardiac gene transfer (256), 
it will be worthy to explore the unique tropism of HBSmut vector via in vivo systemic delivery.  
         Efficient and selective transfer of genes to the cells of interest is crucial for the success of 
gene therapy. Although much work is needed, studies of peptide-modified AAV vectors provide 
a good foundation for addressing these challenges. 
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7. PUBLIC HEALTH SIGNIFICANCE OF THIS STUDY 
MDs have a highly deleterious impact on health, affecting tens of thousands of people in the 
United States and they are one of the major public health problems in several countries. These 
diseases are a significant public health hazard because there is no effective treatment for MDs at 
present. Many cases of MD are new occurrences of the disease without prior family history. 
Although research has discovered much about genetic defects associated with many types of 
MD, treatment for these diseases has not been significantly improved. To provide research with 
respect to the development of effective treatment strategies for various forms of MD, 
investigators have focused on basic and clinical issues related to MD. In this study, a tropism-
modified rAAV vector carried out an efficient and selective gene transfer directed to muscle via 
systemic delivery. The success of specific muscle targeting from peptide-incorporated AAV will 
lead to great advances in the treatment of patients with MD and has the potential to further 
reduce individual suffering and public health care spending.  
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